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Zusammenfassung 
Sinusoidale Leber Endothelzellen (LSEC) exprimieren alle zur professionellen 
Antigenpräsentation nötigen Moleküle wie MHC I und II, geringe Mengen der 
kostimulatorischen Moleküle CD80/86 und das koinhibitorische Molekül B7-H1. Die 
Interaktion von LSEC mit naiven T-Zellen führt zur Induktion von Toleranz. 
Inhalt dieser Arbeit ist die Beschreibung der Mechanismen der effizienten 
Antigenaufnahme und Kreuzpräsentation, sowie der daher möglichen Aktivierung von 
T-Zellen durch LSEC. 
Es zeigte sich, dass die Kreuzpräsentation in LSEC und DC eine sehr unterschiedliche 
Dynamik und Kinetik hat. Systemische, lösliche Antigene wurden bevorzugt in der 
Leber von LSEC aufgenommen und daraufhin effizient kreuzpräsentiert. Die 
Kreuzpräsentation durch LSEC war ex vivo und in vitro deutlich höher als die durch 
dendritische Zellen (DC). Allerdings verblieben von LSEC aufgenommene Antigene 
nicht in LSEC, sondern wurden mit einer Halbwertszeit von nur 6 Std aus LSEC 
eliminiert. Die schnelle Ausschleusung von Antigenen wurde gleichzeitig von einer 
deutlichen Reduktion der Kreuzpräsentation begleitet. In DC kam es im gleichen 
Zeitraum zu keiner signifikanten Reduktion der aufgenommenen Antigene und der 
Kreuzpräsentation.  
LSEC verfügten nicht über ein spezialisiertes endosomales Kompartiment für die 
Kreuzpräsentation löslicher Antigen. Es konnte aber gezeigt werden, dass LSEC 
mehrere Rezeptoren zur Aufnahme von Antigenen für die Kreuzpräsentation nutzen. 
Die dadurch hervorgerufene effiziente Antigenaufnahme könnte das Fehlen eines 
spezialisierten Kompartiments kompensieren. Immunkomplexierte Antigene wurden 
von LSEC nach Aufnahme über den FcRezeptor nur schlecht kreuzpräsentiert. Dies ist 
ein möglicher Mechanismus, um eine Toleranzinduktion gegenüber pathogenen 
Antigenen in Anwesenheit einer humoralen Immunität zu umgehen.  
Weiterhin konnte gezeigt werden, dass LSEC naive T-Zellen nicht nur tolerisieren 
sondern auch aktivieren können. Durch die effiziente Kreuzpräsentation in LSEC wurde 
ein ausreichend starkes T-Zellrezeptorsignal vermittelt, um trotz geringer Kostimulation 
eine IL-2 Produktion in T-Zellen auszulösen. Dieses IL-2 konnte die Toleranzinduktion 
durch LSEC brechen. Die durch LSEC aktivierten T-Zellen zeigten nach 
Restimulierung eine hohe Zytokinproduktion, aber keine Zytotoxizität solange LSEC 
koinhibitorische Signale über B7-H1 vermitteln konnten. Wurden T-Zellen von B7-H1-
defizienten LSEC aktiviert, so produzierten sie stark erhöhte Mengen an IL-2 und 
zeigten Zytotoxizität. Die Aktivierung der naiven T-Zellen konnte durch Blocken von 
IL-2 inhibiert werden. Diese Ergebnisse weisen darauf hin, dass PD-1 die IL-2 
Produktion von T-Zellen negativ beeinflusst. In der Interaktion von LSEC mit naiven T-
Zellen scheint maßgeblich das Vorhandensein oder Fehlen von IL-2 über die Induktion 
von Toleranz oder Immunität zu entscheiden. 
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1 Introduction 
1.1 Brief overview of the immune system 
All mammals have a complex immune system to protect themselves from pathogenic 
agents such as viruses, bacteria and parasites and from mutated cells i.e. tumour cells. 
The first line of defence is the evolutionary old innate immune system, which is present 
in all individuals at all times. However as pathogens can developed much faster than 
mammals, the immune system needs to be able to adapt to and form a memory of 
encountered disease agents, this difficult task is achieved by the acquired or adaptive 
immune system. 
The two systems are not strictly divided but they closely interact. The innate immune 
system (components of which are present in all classes of plant and animal life) consists 
of humoral and cellular defences. Humoral defences consist of the complement system 
(most factors of which are produced by hepatocytes) which can be activated by immune 
complexes linking innate and adaptive immunity, chemokines for recruitment of 
immune cells and cytokines to initiate and shut down immune responses. The cellular 
defences consist of white blood cells which can regulate immune responses by 
producing cytokines, cells that phagocytose and destroy pathogens e.g. neutrophils and 
macrophages and cells that can present antigen e.g. DC and macrophages to elicit an 
adaptive immune response. Innate immune cells must discriminate between self and 
non-self and further between dangerous and innocuous non-self. To meet this challenge 
they carry receptors like Toll like receptors (TLR) and pattern recognition receptors 
(PRR) recognising conserved pathogen associated molecular patterns (PAMPs) (Palm 
and Medzhitov, 2009), (Janeway, 1989).  
The adaptive immune system also constitutes a humoral and cellular part, B cells and T 
cells, respectively. The cells of the adaptive immune system show high specificity and 
are at the same time very versatile due to their expression of receptors recognizing non-
conserved molecules. The possibility of the T and B cell receptor to undergo genetic 
recombination allows a small number of genes to form a nearly infinite number of 
receptors which will then be able to recognize a molecule never encountered before 
(Medzhitov and Janeway, 1997a, b). B cells can also undergo somatic hypermutation 
which makes antibodies more and more specific and increases their affinity over time. 
Efficiency and magnitude of adaptive immune responses increases with increased 
encounters, showing a primary and “secondary” (all following) response. Importantly, 
the adaptive immune response is able to form a memory, conferring life long protection 
from the respective pathogen to the organism. However, cells of the adaptive immune 
system cannot reliably discriminate between self and non-self with potentially 
deleterious consequences to the organism. Therefore adaptive immune responses must 
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be educated by the innate immune system and tightly controlled (Gallegos and Bevan, 
2006; Janeway, 1989; Palm and Medzhitov, 2009). 
1.2 Antigen presentation 
1.2.1 Conventional presentation on MHC class I and II molecules 
The T cell receptor (TCR) cannot recognize foreign antigen by itself. To be recognized 
by T cells antigen has to be processed and peptides loaded onto major 
histocompatibility molecules (MHC). In the case of presentation on MHC class I 
molecules this can be done by every nucleated cell in the body. However, naïve T cells 
which encounter their cognate antigen in absence of co-stimulatory molecules will not 
be activated (hernandez 2001, Jenkins Schwartz 1987).  
Optimal activation of T cells can only be achieved by antigen presenting cells (APC). 
These cells can present peptides on MHC class I molecules to CD8+ T cells and on 
MHC class II molecules to CD4+ T cells in the context of appropriate co-stimulation.  
MHC class II molecules are constitutively expressed only on professional APC such as 
DC, macrophages, B cells, thymic epithelial cells (Jensen, 2007) and also on liver 
sinusoidal endothelial cells (LSEC). For presentation on MHC class II molecules, 
exogenous antigens, soluble or particulate, are taken up into endosomes or phagosomes, 
respectively, which then fuse with lysosomes. Here the protein is enzymatically 
degraded and loaded onto MHC class II molecules that are recruited to the lysosomes 
from the ER. MHC class II peptide complexes travel to the cell surface for recognition 
by CD4+ T cells (Khor and Makar, 2008; Watts, 1997; Wolf and Ploegh, 1995). 
Activated CD4+ T cells can provide help in the activation of B cells and CD8+ T cells or 
develop a regulatory phenotype.  
Antigen derived from within the APC, e.g. from self proteins, intracellular pathogens 
like viruses and some bacteria or from mutated proteins in the case of tumours is 
presented on MHC class I molecules. Proteins are processed within the cytosol by the 
proteasome. Peptides are then transferred by the transporter associated with antigen 
processing (TAP) into the ER where they are loaded onto MHC class I molecules (Rock 
et al., 2004). MHC class I molecules on the cell surface are recognized by CD8+ T cells, 
which once activated can kill target cells.  
1.2.2 Presentation of exogenous proteins on MHC class I molecules (cross-
presentation) 
However APC are not always infected themselves, therefore presentation of exogenous 
antigens on MHC class I molecules, a process termed cross-presentation, is important 
for mounting antigen-specific CD8 T cell immunity. Cross-presented molecules are 
actively taken up by the APC, processed and cross-presented helping to combat 
infection and cancer (Bevan, 1976; Heath et al., 2004; Kurts et al., 1996; Shen and 
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Rock, 2006). APC have been described to acquire antigen for cross-presentation in 
many different ways. The antigen can be particulate e.g. cell associated when an APC 
takes up an apoptotic cell and presents its contents, soluble (taken up by receptor 
mediated endocytosis) or peptides from virally infected cells can even be transferred to 
APC from cell to cell via gap junctions (Neijssen et al., 2005). 
The mechanisms allowing cross-presentation of particulate and soluble antigens by 
professional antigen presenting cells such as dendritic cells or macrophages are 
mechanistically distinct (Ackerman and Cresswell, 2004; Burgdorf and Kurts, 2008). 
Particulate antigens enter phagosomes where MHC class I as well as MHC class II 
restricted antigen-presentation is initiated (Guermonprez et al., 2003; Savina and 
Amigorena, 2007). Soluble antigens in contrast enter early endosomes for exclusive 
presentation on MHC class I molecules. Recently it could be shown by Burgdorf et al 
that a direct link between endocytosis mechanisms and the cell biology of antigen 
presentation exists. Uptake of soluble antigen by receptor mediated endocytosis routed 
antigen into early endosomal compartments for cross-presentation while uptake via 
pinocytosis delivered antigen into lysosomes for MHC class II presentation. 
Furthermore in DC and macrophages not all receptors shuttled soluble antigen into 
endosomes for cross-presentation. The model antigen ovalbumin (OVA) when taken up 
by the mannose receptor was shown to be delivered into a stable early endosomal 
antigen (EEA1+) endosomal compartment which also contained TAP. Peptides could 
thus be loaded onto MHC class I molecules after proteasomal degradation in the cytosol 
within the original endosomal compartment. However if OVA was taken up by the 
scavenger receptor (in macrophages) it was delivered into a lysosomal compartment and 
not cross-presented (Burgdorf et al., 2006; Burgdorf et al., 2008). It has been described 
that the mannose receptor and scavenger receptors by themselves are not sufficient to 
mediate adaptive immune responses (Iwasaki and Medzhitov, 2004). This was verified 
by the observation that TAP which is essential for reintroduction of peptides into 
endosomes is only recruited if a danger signal such as LPS is present (Burgdorf et al., 
2008). This finding suggests that cross-presentation of OVA in DC only ensues when 
danger is sensed at the same time. Differential receptor expression and the ability to 
cross-present soluble antigens provides an explanation to the question why different DC 
subtypes have distinct functional properties (Shortman and Liu, 2002; Villadangos and 
Schnorrer, 2007). However other cell populations capable of cross-presentation could 
employ different mechanisms. Loading of proteins within the ER has been described as 
a further mechanism for cross-presentation in DC (Ackerman et al., 2006; Ackerman et 
al., 2005) and plasmacytoid DC were shown to be able to mediate proteasome 
independent cross-presentation of viral antigens (Di Pucchio et al., 2008). 
LSEC are also capable of cross-presenting soluble exogenous antigens on MHC class I 
molecules to CD8 T cells (Diehl et al., 2008; Limmer et al., 2000; Limmer et al., 2005). 
Furthermore they express the mannose receptor and are very efficient in the uptake of 
soluble antigens. The molecular mechanism of cross-presentation in LSEC is so far 
unknown. However my data show that LSEC utilise different receptors for cross-
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presentation than DC and macrophages. Furthermore cross-presentation in LSEC 
follows distinct kinetics and dynamics rendering them highly efficient. 
 
Figure I. Current model for presentation of exogenous antigen on MHC I and MHC II 
molecules (adapted from (Burgdorf and Kurts, 2008)). Pinocytosis and scavenger receptor 
mediated uptake of soluble exogenous antigen leads to presentation on MHC class II 
molecules in DC and macrophages, respectively (left). OVA taken up by the mannose 
receptor in DC and macrophages is routed into stable early endosomes, processed by the 
proteasome and reintroduced into the endosome for loading onto MHC class I (middle). 
Antigen is taken up by an endocytic receptor shuttled into an early endosome, processed by 
the proteasome and not reintroduced into the endosome, but loaded onto MHC class I 
molecules in another compartment, for example in the ER (putative route of cross-presented 
antigen in LSEC) (right). 
1.3 Induction of T cell immunity 
The activation of naïve T cells is controlled by APC of which DC are the most 
important. In order to fully activate T cells DC must undergo maturation. DC 
maturation is caused by recognition of pathogen derived products (danger signals) or by 
CD4+ T cells via CD40/ CD40L interaction (Mescher et al., 2006).  
Three signals, required for full T cell activation, have been described. The first, signal 1 
is delivered by the TCR specifically recognizing cognate antigen presented on MHC 
class I molecule (Song et al., 2008). Signal 1 alone is not sufficient for the development 
of naïve T cells into mature effector T cells (Bevan, 2006; Schwartz, 2005). The second 
signal is delivered by co-stimulatory molecules expressed on mature APC. Co-
stimulation is mainly delivered by molecules of the B7-family (Collins et al., 2005) 
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such as CD80 (B7.1) and CD86 (B7.2) which are expressed on APC. CD80/86 are 
upregulated upon DC maturation and stimulate CD28, which is expressed by naïve T 
cells. CD28 amplifies TCR signalling and is especially important at low TCR 
occupancy (Acuto and Michel, 2003). The third signal is mediated by proinflammatory 
cytokines such as IL-12 and type I interferons. 
Signalling via CD28 together with TCR induced signalling via the CD3 complex (Lin 
and Weiss, 2001) activates a complex cascade of events, leading to cell cycle 
progression and proliferation (Viola and Lanzavecchia, 1996). CD28 signalling also 
incrases IL-2 receptor expression and production of IL-2, IFNγ and IL-4 (Acuto and 
Michel, 2003). Furthermore signalling via CD28 induces bcl-2 expression promoting T 
cell survival (Collins et al., 2005). 
The full activation of naïve CD8+ T cells and subsequent development of memory 
crucially depends on the presence of signal 2 (co-stimulation) and signal 3 
(proinflammatory cytokines). Especially IL-12 mediating signal 3 is an important 
inducer of IFN-γ production and further has a role in the survival of activated CD8+ T 
cells (Curtsinger et al., 2003). IL-12 is produced by DC in response to danger signals or 
CD40 ligation. IL-12 or type I interferons as a third signal have been shown to be 
required for clonal expansion and the development of cytolytic activity in CD8+ T cells 
(Curtsinger et al., 1999; Curtsinger et al., 2005). Upon APC contact the priming of T 
cells occurs in 3 phases, the first lasting for about 8h resulting in the upregulation of 
activation markers. During the second phase, which lasts for approximately 12h, IL-2 
and IFNγ production are initiated and during the third phase T cell proliferation is 
induced (Henrickson et al., 2008). 
TCR triggering causes a calcium influx into the T cell activating calmodulin. When 
calmodulin has bound calcium it can bind and activate calcineurin which can in turn 
bind to NFAT. NFAT is thereupon dephosphorylated and translocates into the nucleus. 
In T cells NFATc1 and c2 have been described to be of most importance. In the nucleus 
NFAT can initiate the transcription of several cytokines, most importantly IL-2 
(Macian, 2005). CD28 signalling has been shown to mediate IL-2 mRNA stabilization, 
thereby supporting its translation. IL-2 induces clonal expansion (Pei et al., 2008) and is 
crucial for sustained T cell activity (D'Souza and Lefrancois, 2003). Dysfunctions in IL-
2 lead to the development of immunodeficiencies as well as autoimmunity in humans 
and mice, showing that the balance of IL-2 for indcution or prevention of immunity is 
critical (Lan et al., 2008). IL-2 deficient mice show strong lymphoproliferation which 
results in fatal autoimmunity (Sadlack et al., 1994). This phenotype has been shown to 
be due to a severe reduction in CD4+CD25+ Treg (Malek, 2002; Malek and Bayer, 
2004).  
The IL-2 receptor is composed of a α, β and common γ chain. The high affinity IL-2 
receptor (CD25) consists of all 3 chains together. In a positive feedback loop IL-2 can 
increase the expression of its own receptor (Goebel et al., 2006). CD25 is not only 
expressed on regulatory T cells, but is also upregulated on activated T cells, B cells and 
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NK cells (Lan et al., 2008). IL-2 has been described to be able to prevent or reverse the 
induction of T cell anergy (Dure and Macian, 2009). As will be shown here, IL-2 can 
overcome the induction of CD8+ T cell tolerance by LSEC. 
1.4 Induction of T cell tolerance 
1.4.1 Central tolerance 
T cell precursors from the bone marrow develop into naïve T cells in the thymus. Here, 
a highly diverse set of T cells is generated by the rearrangement of genes that encode 
the α- and β- chains of the TCR. A repertoire of antigen receptors is generated which 
can potentially recognize any peptide MHC complex generated, whereas every 
individual TCR is highly specific for a single combination. However this diversity poses 
the risk of T cells recognizing self antigens. The primary mechanism to ensure tolerance 
of T cells towards self antigens is achieved by a process called negative selection. 
During negative selection T cells are tested for their reactivity to self antigens. To this 
end they are presented with a wide range of self antigens by the thymic medullary 
epithelial cells and bone marrow derived macrophages and DC (Gallegos and Bevan, 
2006). The transcription of the diverse self antigens presented by the thymic medullary 
epithelial cells is regulated by the auto-immune regulatory protein (AIRE) (Anderson et 
al., 2002). Those T cells showing a high affinity towards presented self peptide MHC 
complexes are deleted, leading to an elimination of more than 95% of the total T cells 
(Palmer, 2003).  
Although in theory negative selection should eliminate all self-reactive T cells, this is 
not the case, as not all antigens are expressed in the thymus and T cells with low affinity 
TCR can escape negative selection (Liu et al., 1995). Furthermore T cells passing 
successfully through central tolerance cannot distinguish between dangerous non self 
and innocuous non-self antigen (Palm and Medzhitov, 2009). Therefore additional 
tolerance mechanisms are required.  
1.4.2 Peripheral tolerance 
Peripheral tolerance is mediated by several mechanisms such as immune ignorance, 
anergy, peripheral deletion and suppression by regulatory T cells. Cells from the innate 
immune system which can reliably distinguish between self, non-self and dangerous or 
innocuous antigens control tolerance induction or activation of T cells in the periphery 
(Palm and Medzhitov, 2009).  
Immunological ignorance either results from spatial sequestration of antigens to 
immunologically privileged sites like the eye (Alferink et al., 1998; Zinkernagel et al., 
1993) or concentrations of the antigen are too low to trigger T cell activation (Kurts et 
al., 1998). Furthermore self-reactive T cells that have escaped negative selection in the 
thymus most likely express a TCR of low affinity (Zehn and Bevan, 2006) and thus 
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binding of the TCR will not result in activation, the cells remain ignorant. However, 
upon infection and tissue destruction, these self reactive T cells can get into contact with 
previously sequestered or insufficiently presented antigen, which can result in breaking 
of ignorance and the development of autoimmune diseases (Oldstone et al., 1991). 
Presentation of antigen to naïve T cells in the absence of signalling via co-stimulatory 
molecules leads to either T cell deletion (Hernandez et al., 2001) or later T cell 
unresponsiveness called anergy (Jenkins et al., 1987). T cells rendered anergic after 
antigen encounter can survive but remain in an unresponsive state. Anergy is usually 
induced by immature DC, which have not upregulated co-stimulatory molecules and do 
therefore not deliver signal 2 and 3. Endogenous self antigens are constitutively 
presented on MHC I and II molecules by APC under homeostatic conditions. 
Furthermore, DC take up soluble exogenous antigens, waste products and antigens from 
apoptotic cells and can present them on MHC class I molecules leading to the induction 
of cross-tolerance or deletion of CD8+ T cells (Heath et al., 1998; Kurts et al., 1997; 
Luckashenak et al., 2008).  
Furthermore DC not only passively tolerize T cells by presenting antigen in the absence 
of co-stimulation, but can actively induce tolerance through signalling via co-
inhibititory molecules. B7-H1 and B7-DC expressed by DC can interact with the co-
inhibitory molecule PD-1 on T cells (Greenwald et al., 2005) and CD80/86 on DC can 
induce inhibitory signals via cytotoxic T-lymphocyte antigen 4 (CTLA-4) (Waterhouse 
et al., 1995). Co-inhibitory molecules are expressed on naïve T cells and further 
upregulated during priming (Probst et al., 2005).  
Tolerance is not only mediated by APCs but also by regulatory T cells and soluble 
factors (Dhein et al., 1995; Groux et al., 1997). Regulatory T cells (Treg) are 
characterized by their expression of CD4 and CD25. The development and survival of 
Treg crucially depends on the presence of IL-2 (Sakaguchi et al., 2008). Like 
conventional T cells natural CD4+CD25+ Tregs (nTreg) develop in the thymus. Natural 
Treg in contrast to induced Treg express the forkhead-box transcription factor Foxp3 
(Fontenot et al., 2005). Upon antigen encounter Treg inhibit other T cells in an antigen 
unspecific manner. Suppression by Treg is dependent on close proximity to the 
inhibited T cell and has been discussed to be mediated by efficient competition of Treg 
for IL-2, thus sequestering IL-2 from effector T cells (de la Rosa et al., 2004; Scheffold 
et al., 2005). 
Regulatory T cells can also be induced in the periphery by tolerogenic dendritic cells or 
by interaction with CD4+CD25+ Tregs. Induced Treg mediate inhibitory function by the 
production of immune suppressive cytokines transforming growth factor beta (TGF-β) 
and Interleukin 10 (IL-10) (Takahashi and Sakaguchi, 2003). Some of these induced 
regulatory T cells express Foxp3, but show a less stable functional phenotype than 
natural Treg (Sakaguchi et al., 2008).  
Antigen persistence which is seen for self-antigens and in case of a chronic infection 
will enhance the deletion of activated T cells (Davey et al., 2002; Lopes et al., 2008; 
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Redmond et al., 2003). Deletion is mediated by a process called activation induced cell 
death (AICD) which is mediated by the interaction of Fas with Fas ligand expressed by 
activated T cells (Dhein et al., 1995; Singer et al., 1994). 
1.5 The liver 
1.5.1 Tolerance mechanisms in the liver 
The liver plays an important role in the induction of peripheral tolerance. Foreign and 
bacterial antigens derived from the gastrointestinal tract are efficiently cleared to avoid 
the activation of systemic immunity which could lead to generalized organ failure 
(Knolle and Gerken, 2000). The liver microenvironment contains a tolerizing milieu 
which is rich in immune suppressive cytokines. The different hepatic APC all contribute 
to the production of anti inflammatory cytokines. KC, hepatic DC, LSEC and 
hepatocytes can release IL-10 and TGF-β (Bissell et al., 1995; Goddard et al., 2004). 
CD4+ T cells primed by hepatic DC and LSEC differentiate towards regulatory T cells 
and produced IL-10 and IL-4 (Knolle and Gerken, 2000; O'Connell, 2000) and resident 
NKT cells additionally produce IL-13 (Godfrey et al., 2004). IL-10 inhibits the 
immune-stimulatory function of APC and T cells in the liver, leading to a decrease in 
antigen presentation, an inhibition of the production of proinflammatory cytokines like 
IL-12 and IFN-γ and an increase of Prostaglandin E2 (PGE2) production.   
It could recently be shown that adenosine released by liver cells can inhibit T cell 
activation (Linnemann et al, in press). In further support of the tolerizing capabilities of 
the liver is the finding that liver transplants are well accepted and split tolerance 
towards another organ from the same donor can be observed (Knolle and Limmer, 
2003). 
Activated T cells are selectively retained in the liver and deleted by apoptosis (Mehal et 
al., 1999) which could contribute to peripheral tolerance. Two possible mechanisms of 
T cell deletion within the liver are discussed. The “graveyard” hypothesis (Huang et al., 
1994) states that apoptotic cells accumulate in the liver and are then eliminated, while 
the “killing field” hypothesis suggest apoptosis induction as a result of interaction with 
liver cells (Crispe et al., 2000). 
1.5.2 The Liver microanatomy 
The liver has important clearance, metabolic, storage and immune functions. The 
hepatic blood supply consists of 20% o arterial and 80% venous blood, delivered via the 
hepatic portal vein (Knolle and Gerken, 2000). Arterial blood is derived from the 
systemic circulation and is oxygen rich, while venous blood is mostly derived from 
small and large intestine, spleen, pancreas and stomach. Therefore blood arriving via the 
portal vein is rich in food derived and bacterial antigens (e.g. endotoxin) from the gut. 
The liver contains a tight network of small blood vessels, the sinusoids, which are 
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perfused by a mixed arterial/ venous blood flow, coming from the portal field and 
leaving the liver via the central veins converging in the vena cava inferior. The portal 
field contains one biliary duct and one blood vessel derived from the hepatic artery and 
one from the portal vein. The hepatic lymph vessels are also located in this area. The 
blood entering the periportal field is especially rich in antigens and hepatic resident 
macrophages (Kupffer cells) are preferentially located in this area. The entire blood 
volume moves through the liver 360 times per day which facilitates clearance functions 
and immune surveillance. The ample amount of foreign antigen present in the liver 
could easily elicit a local immune response against hepatocytes or, if not cleared, a 
systemic immune response (Knolle and Gerken, 2000). It is therefore vital that 
hepatocytes are protected from passenger immune cells to efficiently detoxify and clear 
waste and bacterial products. 
Furthermore hepatocytes are involved in protein synthesis producing plasma proteins, 
acute phase proteins (Billiar et al., 1992; Knolle and Limmer, 2003), mannose binding 
proteins, C-type lectins, fibrinogen, complement factors, albumin which is a major 
osmolar component of the blood and proteins and biochemicals implicated in digestion 
e.g. bile for emulsifying lipids. Also they play an important role in glucose metabolism 
(Leclercq et al., 2007), as hepatocytes can build glycogen from glucose (glycogenesis) 
for subsequent storage. Glycogen can later be broken down into glucose again 
(gluconeogenesis).  
1.5.3 Cell populations of the liver sinusoid 
The liver sinusoids make up a mesh of minute blood vessels, with a diameter of only 5-
7µm (MacPhee et al., 1995; Wisse et al., 1985) and a very slow flow rate of 
approximately 25-250µm/ min (MacPhee et al., 1992, 1995). The sinusoids are lined by 
the sinusoidal endothelial cells (LSEC). LSEC make up a discontinuous endothelium, 
not forming tight junctions and not containing a basement membrane (Racanelli and 
Rehermann, 2006). Furthermore LSEC contain little pores called fenestrae with 
approximately 100nm diameter (Wisse, 1970). LSEC are in direct contact with 
passenger cells on the luminal side, but are divided from hepatocytes on the apical side 
by the perisinusoidal space of Dissé (Smedsrod et al., 1994). The space of Dissé 
contains extracellular matrix (Knolle and Gerken, 2000) produced by the resident 
hepatic stellate cells (HSC). In absence of inflammation leukocytes cannot move into 
the space of Dissé and are therefore usually not in direct contact to hepatocytes, as 
LSEC form a shield in between them (Limmer et al., 1998). However it has been 
observed that T cells can form little protrusions and touch hepatocytes through the 
endothelial fenestrae, the function of this interaction is so far unknown (Warren et al., 
2006). 
The parenchymal hepatocytes constitute the major cell population in the liver. 
Hepatocytes can contain several nuclei and are mainly responsible for metabolism in the 
liver. Hepatic stellate cells (HSC) residing in the space of Dissé store vitamin A 
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contained in lipid droplets within their cytosol. As vitamin A is autofluorescent in ultra 
violet light HSC are easily identified. Usually HSC are found to be in a quiescent state 
(Geerts, 2007) expressing long protrusion which are wrapped around the sinusoids and 
can contract, thus controlling sinusoidal diameter (Oda et al., 2000). HSC have been 
shown to be able to interact with NKT cells presenting lipid antigens to them (Winau et 
al., 2007). When activated upon liver injury HSC can transdifferentiate into fibroblasts 
and produce collagen. They have been implicated in being the main cell population 
responsible for liver fibrosis. 
The liver hosts a large population of resident macrophages the Kupffer cells (KC). KC 
constitute the largest population of macrophages in the organism (Racanelli and 
Rehermann, 2006). They efficiently take up particulate antigen by phagocytosis and are 
responsible for clearance of bacterial products and apoptotic cells (Elvevold et al., 
2008b). Furthermore KC can move through the Space of Dissé and clear dead 
hepatocytes (Racanelli and Rehermann, 2006). 
The liver also contains a hepatic DC (HDC) population displaying an immature, 
tolerogenic phenotype (Banchereau et al., 2000). HDC are mainly located around the 
central veins. Upon activation they can migrate via the Space of Dissé to the lymphatics 
in the portal tract and subsequently to extra hepatic lymph nodes (Kudo et al., 1997).
The lymphocyte populations found in the liver are distinct from those found in 
lymphatic organs. Hepatic lymphocytes show an increased proportion of NK, NKT and 
γδ T cells. Furthermore the T cell population in the liver is enriched in CD8+ T cells. T 
cells in the liver, rather than being naïve, mainly exhibit a matured effector or memory 
phenotype (Crispe et al., 2006). 
1.5.4 The liver sinusoidal endothelial cell (LSEC) 
The liver contains 3 populations of endothelial cells, which are located macrovascular, 
periportal and perivenous. They can all be stained by the endothelial cell specific 
marker ME9 F1 (CD146). However functionally they are distinct. The macrovascular 
endothelial cells do not express scavenger receptors or C-type lectin receptors and 
consequently display no scavenger function towards soluble antigen (Knolle and 
Limmer, 2003). Periportal and perivenous LSEC both express scavenger and C-type 
lectin receptors, periportal LSEC however have been shown to be more efficient in 
antigen uptake irrespective of the amount of antigen present (Vidal-Vanaclocha et al., 
1993a).  
Lining the liver sinusoids LSEC are in direct contact with passenger leukocytes. They 
have a unique phenotype resembling professional antigen presenting cells, as they 
express surface molecules usually only found on cells from myeloid origin (Knolle and 
Limmer, 2003). LSEC constitutively express MHC class II and the co-stimulatory 
molecule CD40 enabling them to interact with CD4+ T cells, in which they induce a 
regulatory phenotype (Knolle and Limmer, 2003; Knolle et al., 1999). Furthermore 
LSEC express MHC class I molecules and the co-stimulatory molecules CD80/86 albeit 
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the latter at low concentrations. Constitutively the co-inhibitory molecule B7-H1 is 
expressed shown to be instrumental in induction of tolerance in naïve CD8+ T cells 
(Diehl et al., 2008). To aid interaction with T cells the adhesion molecules ICAM 
(CD54) and VCAM are expressed and can be upregulated in response to bacterial 
endotoxin (Knolle and Gerken, 2000). Importantly LSEC have been shown to be able to 
cross-present exogenous soluble antigen on MHC class I molecules to CD8+ T cells 
This finding clearly shows that LSEC function as resident antigen presenting cells 
(Limmer et al., 2000).  
 
Figure II. LSEC have a unique phenotype, resembling an antigen presenting cell. LSEC 
express adhesion molecules like ICAM (CD54) and VCAM (CD106), endocytic receptors 
and all molecules for professional antigen presentation.  
LSEC play an important role in liver homeostasis as I and others have found that they 
are the hepatic cell population most important for the clearance of soluble antigen from 
the circulation (Elvevold et al., 2008b; Malovic et al., 2007). Although LSEC contain 
fenestrae with a diameter of about 100nm even small particles like colloidal gold of 
only 15nm size cannot pass freely through them. Colloidal gold after i.v. injection was 
always only found in the sinusoidal lumen, but never in the space of Disse (Kempka and 
Kolb-Bachofen, 1988). This finding suggests that clearance of soluble molecules by 
LSEC is achieved predominantly by receptor mediated endocytosis. In line with this 
finding, LSEC express several C-type lectin and scavenger receptors.  
 
Receptor Ligand Reference 
Mannose receptor (MR) Mannose, denatured 
collagen 
(Magnusson and Berg, 1989)  
L-SIGN, LSECtin (human) 
mSIGNR1 (mouse) 
Mannose, glycoproteins 
(hepatitis C virus) 
(Koppel et al., 2005) 
(Cormier et al., 2004) 
oxidised low density 
lipoprotein receptor 1 
(LOX 1) 
apoptotic cells, Gram+/- 
Bac, aged red blood cells, 
oxidized-low density 
lipoprotein (OxLDL) 
(Shimaoka et al., 2001)  
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Stabilin I and II hyaluronan 
glycosaminoglycans 
(Smedsrod et al., 1990)  
Macrophage scavenger 
receptor SR-AI/ II 
(CD204) 
negatively charged ligands, 
acetylated low densitiy 
lipoprotein (Ac-LDL), 
OxLDL, advanced 
glycation end products 
(AGEs) 
(Smedsrod, 2004)  
Scavenger receptor class B 
SR-B (CD36) 
Collagen, OxLDL, fatty 
acids, Plasmodium 
falciparum 
(Tandon et al., 1989) 
(Nicholson et al., 1995) 
(Oquendo et al., 1989) 
 
The mannose receptor (MR) has been shown to mediate cross-presentation of soluble 
ovalbumin (OVA) by DC (Burgdorf et al., 2007). However, on LSEC the very versatile 
MR has multiple functions. The MR contains 3 distinct binding domains, the CysR 
domain binds sulphated oligosaccharides (e.g. pituitary hormones), the FNII domain is 
the collagen binding domain and the CTLD4 domain is a Ca2+ dependent sugar binding 
domain recognising terminal mannose, fucose and N-acetylglucosamine (Boskovic et 
al., 2006) and plays a role in the recruitment of lysosomal enzymes (Elvevold et al., 
2008a). The MR expressed on murine LSEC has been shown to be the main collagen 
clearance receptor for denatured collagens (Malovic et al., 2007) and functions as a 
pattern recognition receptor, as for example some viruses are highly mannosylated 
(Elvevold et al., 2008b). 
LSEC and KC also express the FcγRII B1/ 2 (CD32) and FcγR III (CD16) and can bind 
antibody/ antigen complexes by the Fc domain of immunoglobulin G. Larger immune 
complexes > 1µm are cleared through phagocytosis by KC and are not taken up by 
LSEC (Smedsrod, 2004). Small soluble immune complexes can be internalized by 
LSEC (Lovdal et al., 2000), however, this work shows, that in contrast to molecules 
taken up by scavenger and C-type lectin receptors, immune complexed antigens are 
differentially routed and badly cross-presented by LSEC. In contrast, in DC 
opsonization of antigen was shown to lead to maturation and enhanced antigen uptake 
and presentation (Regnault et al., 1999). 
Molecules taken up by LSEC can be transported through the cell in a process called 
transcytosis and then be passed on to hepatocytes for metabolism or excretion via the 
bile. Transcytosis has been demonstrated for transferrin and ceruloplasmin (Tavassoli et 
al., 1986a; Tavassoli et al., 1986b). However pathogens like hepatitis B and C virus can 
exploit this mechanism, as they are endocytosed by LSEC and then transferred to 
hepatocytes in which they replicate (Breiner et al., 2001; Cormier et al., 2004).  
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LSEC seem not to play a major role in metabolism of endocytosed molecules, as 
transport to lysosomal compartments was shown to be relatively slow (Hellevik et al., 
1998). 
Finally LSEC also express the toll like receptor TLR 4 and have been shown to be able 
to react to very low amounts of endotoxin, resulting in the production of pro 
inflammatory mediators i.e. IL-6, signalling the hepatocytes (which do not express TLR 
themselves) to produce acute phase proteins. However, IL-6 production is tightly 
regulated and LSEC become unresponsive upon repetitive stimulation (Knolle and 
Limmer, 2003; Knolle et al., 1997). 
 
Figure III. Transcytosis in LSEC. Uptake of soluble antigen from the simusoidal lumen 
and transfer to the Space of Dissé. 
1.5.5 Tolerance induction by LSEC  
An important contribution to the peripheral tolerance established in the liver is made by 
LSEC. As LSEC line the sinusoids they get into intimate contact with passenger cells. 
LSEC can suppress neighbouring DC in their capacity to prime naïve T cells 
(Schildberg et al., 2008) and furthermore LSEC are very efficient antigen presenting 
cells as will be shown for antigen cross-presentation to CD8+ T cells in this work. LSEC 
are endowed with extraordinary scavenger activity and take up circulating antigens from 
the blood to present them to passenger T cells that migrate through the sinusoids. 
Exogenous soluble antigens can be presented by LSEC in a process termed cross-
presentation (described in more detail below) on MHC class I molecules to CD8+ T 
cells (Limmer et al., 2000). Cross-presentation by LSEC ultimately leads to the 
induction of T cell tolerance. However naïve CD8+ T cells first undergo an initial 
activation phase during which they upregulate activation markers like CD44 and CD69 
and the high affinity IL-2Rα (CD25). Antigen specific interaction of T cells with LSEC 
induces a tolerogenic maturation in the latter (Diehl et al., 2008). B7-H1 which is 
constitutively expressed on LSEC and can deliver an inhibitory signal to T cells via PD-
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1 is strongly upregulated upon interaction with T cells. This tolerogenic maturation is 
unique to LSEC and has not been observed to occur on DC (Diehl et al., 2008). B7-H1 
PD-1 interaction has been described to stimulate naïve T cells (Dong et al., 1999) and 
inhibit activated ones (Freeman et al., 2000). In LSEC B7-H1 is mandatory for the 
induction of tolerance as B7-H1 deficient LSEC fully activate naïve T cells to become 
effector cells (Diehl et al., 2008). LSEC upon interaction with T cells do not up regulate 
the co-stimulatory molecules CD80/86 which are expressed at low levels. Importantly 
in the contrast to T cells primed by DC, those primed by LSEC produced no detectable 
amounts of IL-2 upon activation. However, T cells are induced to undergo clonal 
expansion and the magnitude of proliferation during the first 3 days following priming 
was indistinguishable to that induced by activating DC (Diehl et al., 2008). When T 
cells primed by LSEC are restimulated by CD3 triggering on day 4 or 5 post priming 
they fail to produce IFN-γ and IL-2 and show no cytotoxicity (Limmer et al., 2000). 
Furthermore T cells show a tolerized phenotype characterized by the expression of 
CD44 and CD62L but not CD25. However they express the survival factor Bcl-2 and 
the homeostatic cytokine receptor IL-7Rα suggesting that rather than being deleted 
LSEC tolerized T cells survive (Diehl et al., 2008). In contrast, the interaction of LSEC 
with activated T cells has been reported to induce T cell apoptosis (Huang et al., 1994). 
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The liver is an organ fulfilling important clearance, metabolic and immune functions 
and has been shown to be instrumental in the induction of peripheral tolerance. LSEC, 
which line the liver capillaries, are highly efficient scavenger cells for soluble antigen. 
Furthermore they have a unique phenotype, resembling a professional APC. They 
constitutively express MHC class I and II molecules, the co-inhibitory molecule B7-H1 
and co-stimulatory molecules CD80/86, albeit the latter at low concentrations. LSEC 
can present exogenous antigens to CD8+ T cells, inducing tolerance. By efficiently 
clearing foreign antigen from the circulation, LSEC help to sustain peripheral tolerance. 
However, tolerance induction by LSEC can be exploited by pathogens like Hepatitis B 
and C virus. 
Therefore it is of importance to understand the mechanisms of cross-presentation 
employed by LSEC to aid the induction of tolerance against self-proteins in case of an 
autoimmune disease or the induction of immunity in case of a persistent infection.  
In this work, the molecular mechanisms allowing cross-presentation in LSEC are 
investigated and directly compared to the mechanisms employed by dendritic cells, 
thereby identifying unique mechanisms that allow LSEC to combine scavenger function 
and high antigen-turnover with cross-presentation. Furthermore the role of the effector 
cytokine IL-2 in governing the outcome of T cell priming by LSEC was examined.  
In this thesis the following questions were addressed: 
 
• Which cells are responsible for the clearance of systemic circulating antigens? 
 
• How efficient is antigen cross-presentation by LSEC in comparison to DC, ex 
vivo and in vitro? 
 
• What mechanisms of antigen uptake and routing for cross-presentation do LSEC 
employ to accommodate antigen turn-over and cross-presentation? 
 
• What is the functional outcome of cross-presentation by LSEC and can the high 
amount of presented antigen sufficiently stimulate T cells for activation, 
although co-stimulation is low? 
 
• Which role does IL-2 play in the induction or prevention of tolerance by LSEC? 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Mice 
C57BL/6 Inbred mouse strain expressing the MHC class I haplotype H2Kb
MR-/- Deficiency of the mannose receptor 
OT-1 x Rag OT-1 x Rag transgenic CD8+ T cells with an H2Kb-SIINFEKL 
restricted Vα2Vβ5 TCR bred with recombination–activating gene 
1-deficient mice 
DesTCR TCR transgenic recognising three endogenous peptides presented in 
the context of H2Kb (Guimezanes et al., 2001; Schonrich et al., 
1991)  
B7-H1-/- Deficiency of the B7-H1 (PD ligand 1) molecule 
CD80/86-/- Deficiency of the CD80 and CD86 (B7.1 and B7.2) molecules 
St35 Transgenic CD8 T cells with an H2Kb-SGPSNTPPEI restricted TCR, 
show low avidity towards the cognate antigen due to low TCR 
expression. SGP is an adenovirus E1a protein derived peptide. 
All mice were on the C57BL/6 background. Experimental animals were bred under 
specific pathogen free (SPF) conditions according to the FELASA guidelines in the 
central animal facility “Haus für Experimentelle Therapie” (HET) at the University 
Hospital Bonn. For all experiments mice between 6-20 weeks of age were used in 
accordance with local animal experimentation guidelines. 
3.1.2 Cell lines 
B3Z CD8+ T cell hybridoma expressing a TCR recognising the OVA257-264 
peptide in the context of H2Kb, TCR signalling triggers the 
expression of the bacterial reporter gene lacZ (β-galactosidase gene) 
placed under the control of the NFAT IL-2 enhancer element. Upon 
activation B3Z produce IL-2 and β-galactosidase  
DC2.4 Mouse DC cell line expressing H2Kb 
RMA NK cell hybridoma, expressing H2Kb  
Ag8653 GM-CSF producing hybridoma 
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3.1.3 Antibodies 
3.1.3.1 Flow cytometry 
Target Host Clone Supplier 
CD146 Rat IgG2a ME9F1 Own production 
CD11c Hamster IgG1 HL3 BD biosciences 
Heidelberg 
CD8a Rat IgG2a 53-6.7 BD biosciences, 
Heidelberg 
CD3 Hamster IgG  145-2C11 ebiosciences, San 
Diego 
CD25 Rat IgG2b 3C7 BD biosciences, 
Heidelberg 
CD44 Rat IgG2b IM7 BD biosciences, 
Heidelberg 
CD62L Rat IgG2a MEL-14 BD biosciences, 
Heidelberg 
CD69 Hamster IgG1 H1.2F3 BD biosciences, 
Heidelberg 
CD11b Rat IgG2b κ M1/70 BD biosciences, 
Heidelberg 
CD19 Rat IgG2a κ 1D3 BD biosciences, 
Heidelberg 
IFN-γ Rat IgG1 XMG1.2 ebiosciences, San 
Diego 
H2Kb Mouse IgG2a AF6-88.5 BD biosciences, 
Heidelberg 
H2Kb:SIINFEKL Mouse 25D1.16 Own prodcution 
CD204 Rat IgG2b  Serotec, Düsseldorf 
LOX1 Goat M17 Santa Cruz 
Biotechnologies, USA 
L-SIGN IgM ERTR9 BMA, Augst 
MR Rat MR 5D3 Serotec, Düsseldorf 
CD16/32 Rat IgG2b 2.4G2 Own production 
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TCRβ Hamster IgG H57-597 BD biosciences, 
Heidelberg 
Antibodies for flow cytometry were either directly fluorochrome labelled or 
biotinylated and detected by fluorochrome conjugated Strepavidin (BD biosciences). 
3.1.3.2 Immunofluorescence 
Primary Antibodies 
Target Host  Clone Fluorochrome Supplier 
EEA1 Rabbit D1707 Pure Santa Cruz 
Biotechnology, USA 
Calnexin Rabbit  Pure Abcam, Cambridge 
LAMP1, 
CD107a 
Rat IgG2a 1D4B Pure ebiosciences, San 
Diego 
MR Rat IgG2a MR 5D3 Alexa 647/ A488 Serotec, Düsseldorf 
Tap 1 Goat  Pure Santa Cruz 
Biotechnology, USA 
Rab11 Rabbit H87 Pure Santa Cruz 
Biotechnology, USA 
Rab7 Goat  Pure Santa Cruz 
Biotechnology, USA 
Secondary Antibodies 
Target Host  Clone Fluorochrome Supplier 
Goat Donkey  Texas Red Santa Cruz 
Biotechnology, USA 
Rabbit Sheep  DyLight 649 Serotec, Düsseldorf 
Rabbit Goat  Alexa 568 Invitrogen, Karlsruhe 
Rat Goat  Alexa 568 Invitrogen, Karlsruhe 
To block unspecific and FcR mediated binding of antibodies, serum was used for 
blocking. Mouse, rat and goat sera were purchased from Caltag, Carlsberg, USA. 
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3.1.4 Western Blot 
Primary Antibodies 
Target Host Clone Fluorescence Supplier 
β-Actin Rabbit  Pure  Sigma, Steinheim 
OVA Rabbit  Serum Kindly provided by 
A. Tittel 
OVA Mouse KB4 F6 Pure  Own production 
OVA Mouse KB4 3B11 Pure Own production 
Secondary Reagents 
Target Host Clone Conjugation Supplier 
Rabbit Goat  HRP Santa Cruz 
Biotechnology, USA 
Mouse Goat  HRP Santa Cruz 
Biotechnology, USA 
3.1.4.1 Functional antibodies 
Target Host Clone Conjugation Supplier 
IL-2 Rat IgG2b JES6 1A12 pure ebiosciences, San 
Diego 
CD3 Hamster IgG 145 2C11 pure Own production 
NK1.1 Mouse 
IgG2a 
PK136 pure Own production 
3.1.5 ELISA 
Target Host Clone Conjugation Supplier 
IL-2 Rat IgG2b JES6 1A12 pure ebiosciences, San 
Diego 
IL-2 Rat IgG2b JES6 5H4 biotinylated ebiosciences, San 
Diego 
IFN-γ Rat IgG1 R46A2 pure Own production 
IFN-γ Rat IgG1 AN 6A2 biotinylated Own production 
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3.1.6 Antibody coated beads 
Anti-CD146 (MACS)  Miltenyi, Bergisch Gladbach 
Anti-CD11c (MACS)  Miltenyi, Bergisch Gladbach 
Anti-CD8 (MACS)  Miltenyi, Bergisch Gladbach 
3.1.7 Fluorochrome labelled ligands 
OVA Alexa 647/ 488  Invitrogen, Karlsruhe 
AcLDL Alexa 488  Invitrogen, Karlsruhe 
BSA Alexa 647  Invitrogen, Karlsruhe 
Transferrin Alexa 647  Invitrogen, Karlsruhe 
3.1.8 Fluorochromes 
Hoechst 33258  Sigma, Steinheim 
CFSE  Invitrogen, Karlsruhe 
Violet dead cell  Invitrogen, Karlsruhe 
3.1.9 Enzymes 
Collagenase  Sigma, Steinheim 
Accutase  PAA, Pasching 
Peroxidase  Pierce, Rockford, USA 
Trypsin/ EDTA   Gibco BRL, Karlsruhe 
3.1.10 Proteins and synthetic peptides 
S8L  BWG, Ebersberg 
SGP  Kindly provided by H.J. Schild 
OVA  Serva, Heidelberg 
BSA  Roth, Karlsruhe 
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3.1.11 Inhibitors 
Poly inosinic potassium 
acid 
 Sigma, Steinheim 
Mannan  Sigma, Steinheim 
Brefeldin A  ebiosciences, San Diego 
Chloroquine  Sigma, Steinheim 
Bafilomycin  Sigma, Steinheim 
Epoxomicin  Sigma, Steinheim 
Primaquine  Sigma, Steinheim 
BNLF2a  Kindly provided by E.Wiertz 
3.1.12 Cell culture media  
LSEC medium  
 
  DMEM high Glucose (4500 mg/l)  
10% FCS (v/v)  
105 U Penicillin, 0.1 g/l Streptomycin  
2mM L-Glutamine 
 
T cell medium 
 
  RPMI 1640  
10% (v/v) FCS  
105 U Penicillin 
0.1g/l Streptomycin  
2mM L-Glutamine  
50µM β-mercaptoethanol 
 
3.1.13 Cytokines 
Interleukin 2  Peprotech, Rocky Hill, USA 
Interferon-γ  Peprotech, Rocky Hill, USA 
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3.1.14 Buffers and Solutions 
PBS (phosphate buffered 
saline) 
 80g/l NaCl 
0.2g/l KCl 
1.44g/l NaHPO4*2 H2O 
0.2g/l KH2PO4
pH 7.4 
(Fa. Biochrom) 
 
GBSS (Gey’s balanced 
salt solution) 
 137mM NaCl  
5mM KCl 
1.6mM CaCl2 
0.9mM MgCl2  
0.3mM MgSO4  
0.2mM KH2PO4  
1.7mM Na2HPO4 pH 7.4  
2.7mM NaHCO3  
5.5mM D(+)-Glucose  
50mM HEPES  
pH 7.4  
 
MACS/ FACS buffer  PBS  
1% (v/v) FCS  
2mM EDTA  
pH 7.2 
 
EDTA (0.5M)  186.1g EDTA  
approx. 20g NaOH  
1000ml H2O  
pH 7.8-8.0  
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ACK Lysis buffer  16.58g NH4Cl  
2g KHCO3  
74.4mg EDTA  
2000ml H2O  
pH 7.2-7.4 
 
Coating buffer for 
ELISA 
 0.1M Na2HPO4, pH 9 
Blocking buffer for 
ELISA 
 1% (w/v) BSA in PBS 
Washing buffer for 
ELISA 
 0.05% (v/v) Tween-20 in PBS 
ABTS buffer for ELISA 
detection 
 17.89g citric acid, monohydrate 
1000ml H2O 
pH 4.35 
 
Perfusion buffer   0.01g L- Aspartic acid  
0.02g L-Threonine  
0.03g L-Serine  
0.04g Glycine  
0.05g L-Alanine  
0.13g L-Glutamic acid  
0.13 g L-Glutamine  
3.6g D(+)-Glucose  
3.6g D(-)-Fruktose  
67.4g Sucrose  
0.22g KCl  
0.1g NaH2PO4* H2O  
0.1g MgCl2* 6 H2O  
2.4g HEPES  
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2.0g NaHCO3  
1000ml H2O  
0.05% (v/v) Collagenase  
 
Protein loading buffer  0.58M Sucrose 
4% (w/v) SDS 
0.04% (v/v) Bromphenol blue 
62.5mM Tris/Hcl, pH 6.8 
60mg/ ml DTT 
SDS running buffer  125mM Tris 
192mM Glycin 
0.1% (w/v) SDS 
Stripping buffer  100mM 2-mercaptoethanol 
2% (w/v) SDS 
62.5mM Tris/Hcl, pH 6.8 
TBS (10x)  200mM Tris 
1.26M NaCl pH 7.6 
TBS/ T  TBS 
0.1% (v/v) Tween 20 
Transfer buffer   25mM Tris 
192mM Glycin 
0.1% (w/v) SDS 
20% (v/v) Methanol 
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3.1.15 Chemicals and Reagents 
Citric acid monohydrate 
(C6H8O7*H2O) 
 Sigma, Steinheim 
D(-)-Fructose (C6H12O6, 
MW = 180.2)  
 Sigma, Steinheim 
D(+)-Glucose (C6H12O6, 
MW = 180.2)  
 Sigma, Steinheim 
Disodium hydrogen 
phosphate (Na2HPO4, 
MW = 142)  
 Sigma, Steinheim 
EDTA  Roth, Karlsruhe 
Ethanol, absolute 
(C2H4O2, MW = 46.07) 
 Applichem, Darmstadt 
Fetal Calf Serum (FCS)  PAA, Pasching, Österreich 
Glycine (C2H5NO2, MW 
= 75.07)  
 Sigma, Steinheim 
HEPES (C8H18N2O4S, 
MW = 238.3)  
 Sigma, Steinheim 
Hydrogen peroxide 
(H2O2, MW = 34.0) 
 Pharmacy of the University of Bonn 
L-Glutamine (200 mM) 
(C5H10N2O3) 
 Cambrex, Verviers, Belgien 
Lymphocyte separation 
medium 
 Nycomed Pharma, Unterschleissheim 
Magnesium chloride 
(MgCl2*6 H2O, MW = 
203.3)  
 Merck, Darmstadt 
Magnesium chloride, 50 
mM  
 Invitrogen, Karlsruhe 
Magnesium sulfate 
(MgSO4, MW = 120.4)  
 Sigma, Steinheim  
Monopotassium 
phosphate (KH2PO4, 
MW = 136.09) 
 Gerbu, Gaiberg 
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Monosodium phosphate 
(NaH2PO4, MW = 
120.0)  
 Merck, Darmstadt 
Nycodenz  Axis-Shield, Norwegen 
Paraformaldehyde (PFA) 
(H(-OCH2)n-OH) 
 Fluca, Buchs 
PBS  Biochrom, Berlin 
Percoll   
Potassium bicarbonate 
(KHCO3, MW = 100.12)  
 Sigma, Steinheim 
Potassium chloride 
(KCl, MW = 74.55)  
 Merck, Darmstadt 
RPMI 1640 Medium  Gibco BRL, Karlsruhe 
Sodium azide (NaN3, 
MW = 65.01) 
 Sigma, Deisenhofen 
Sodium bicarbonate 
(NaHCO3, MW = 84.01)  
 Sigma, Steinheim 
Sodium chloride (NaCl, 
MW = 58.44)  
 Merck, Darmstadt 
Sodium hydroxide 
(NaOH, MW = 40.0)  
 Merck, Darmstadt 
Streptomycin (10 
mg/ml)/ Penicillin 
(10,000 U/ml) 
 PAA, Pasching, Österreich 
Sucrose  Sigma, Steinheim 
Tris base  Roth, Karlsruhe 
Trypan Blue  Serva, Heidelberg 
Tween-20   Merck, Darmstadt  
β-mercaptoethanol 
(HS(CH2)2OH, MW 
=78.13) 
 Sigma, Deisenhofen 
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3.1.16 ELISA substrates 
ABTS  Sigma, Steinheim 
TMB  Pierce, Bonn 
3.1.17 Equipment 
AutoMACS  Miltenyi, Bergisch Gladbach 
Centrifuges  Heraeus, Hanau 
ELISA reader Spectra 
MAX 250 
 MWG Biotech, Hamburg 
Elutriator Avanti J25I  Beckman Coulter, Krefeld 
FACSorter, DIVA   Becton Dickinson, Heidelberg 
Flow cytometer, CantoII  Becton Dickinson, Heidelberg 
Flow cytometer, LSRII  Becton Dickinson, Heidelberg 
Incubators, Hera cell  Heraeus, Hanau 
Microscope IX71  Olympus, Hamburg 
Microscope IX81  Olympus, Hamburg 
Microscope, Confocal 
FV 1000 
 Olympus, Hamburg 
Perfusion pump, 
Masterflex 
 Cole-Parmer Instrument Company via 
Novodirect, Kehl/Rhein 
pH-meter, pH 523  WTW, Weilheim 
Pipette, Multipipette® 
plus 
 Eppendorf, Hamburg 
Pipetter, cordless  Matrix Technologies CellMate® Thermo 
Scientific, USA 
Pipettes, 0.2-2 µl, 0.5-5 
µl, 2-20 µl, 10µl-100µl, 
20-200 µl, 100-1000µl 
 Gilson, Limburg-Offheim 
 
Preparation instruments  Labotec, Göttingen 
Shaking Waterbath 
GFL® 1092 
 GFL®, Burgwedel 
Sieves, steel  University of Bonn, Department 
„Feinmechanik“ 
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Sonificator  UW2070/Sonoplus (Bandeln electronic, 
Berlin) 
Spectrophotometer 
Ultrospec 3100 pro 
 Amersham biosciences, Piscataway 
Spectrophotometer, 
NanoDrop™ ND 1000 
 NanoDrop Products, Wilmington, USA 
Threaded bottles,100 ml, 
250 ml, 500 ml, 1000 
ml, 1 l, 2 l 
 Schott, Mainz 
Ultrapure water system, 
NANOpure Diamond, 
Barnstead 
 Werner Reinstwassersysteme, Leverkusen 
Vibratom VT 1000S  Leica, Wetzlar 
Workbench, sterile, Hera 
safe 
 Heraeus, Hanau 
TE77 Semi-dry transfer 
unit 
 Amersham biosciences, Piscataway 
Electrophoresis chamber 
SE600 Ruby 
 Amersham biosciences, Piscataway 
3.1.18 Software 
Analysis Microscopy analysis Olympus 
Excel 2004 for Mac  Data analysis Microsoft 
FACS Diva V6.1.1 FACS analysis BD 
Flowjo V8.7.1 FACS analysis Tree star, Inc. 
Illustrator CS V11.0.0 Graphic design Adobe 
Photoshop Graphic design Adobe 
Prism 4 for Macintosh  Statisitics and graphic design GraphPad Software 
Scan R Microscopy analysis Olympus 
Word 2004 for Mac Data analysis Microsoft 
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3.2 Methods 
3.2.1 Primary cell isolation 
All mice used in the experiments were between 6-20 weeks of age. Mice were sacrificed 
by CO2 mediated asphyxiation. Body surfaces were cleaned with 70% ethanol and 
subsequently the body cavity was opened under semi sterile conditions.  
3.2.2 Purification of LSEC 
3.2.2.1 Perfusion of the liver 
In order to successfully isolate endothelial cells from the liver, the liver tissue needs to 
be digested, this is best achieved by perfusion of the liver with collagenase. 
Material Perfusion pump, 25G Needle, Perfusion buffer GBBS (Ca2+ 
deprived) containing 0.05% (w/v) collagenase or 4% (w/v) PFA 
Method Cannulation of the portal vein and subsequent opening of the vena 
cava inferior. The liver is then perfused with perfusion buffer for 
approx. 10s at a pump speed of 3ml/ min until it turns light. Liver is 
removed from the abdomen, gallbladder is cut carefully. Liver is kept 
in GBSS. 
If the liver is to be fixed to prepare tissue sections for microscopy, it 
is perfused with 4% w/v PFA. Liver is then cut into cubes and thin 
50-100µm slices are cut using a vibratom. 
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3.2.2.2 Separation of non-parenchymal from parenchymal cells by gradient 
centrifugation 
Material  Scissors, metal filter, GBBS with 0.04% (w/v) collagenase, 
Nycodenz solution, Percoll solution 
Method Livers are transferred into a petri-dish and softened tissue is torn 
away using scissor blades, livers are minced. Subsequently, livers are 
transferred into a 50ml “Falcon”, GBSS with 0.04% w/v collagenase 
tube and shaken in rotary water bath at 240rpm for 17min at 37°C. 
The cell suspension is passed through a metal filter (mesh size 
250µm) and centrifuged (10min, 350xg, 20°C). The supernatant is 
discarded and 30% w/v Nycodenz is added at 1.23 times the volume 
to the remaining cell solution (final density of solution 1.089g/ cm3). 
The suspension is overlaid with approx. 500ul of GBSS. Cells are 
centrifuged at 1400xg for 20min at room temperature. Cells are 
recovered from interface and centrifuged (10min, 350xg, 20°C). 
LSEC are finally isolated via centrifugal elutriation or MACS 
separation. If liver cells are prepared solely for flow cytometric 
staining a Percoll gradient is used. Cells are taken up in 40% v/v 
Percoll and underlaid with 80% v/v Percoll and centrifuged (20min, 
800xg, 20°C). Cells are recovered from interface and centrifuged 
(10min, 350xg, 20°C). 
3.2.2.3 Isolation of LSEC by gradient elutriation 
The gradient elutriation allows a separation of cells according to their size and density. 
The separation is achieved by running cells at a certain flow speed through a 
centrifuge. The speed of flow determines cells of which size are separated, the faster 
the flow the bigger the cells obtained. 
Material Elutriation centrifuge: J2-MC with Rotor ‘JE-6B’, LSEC medium 
Method Centrifuge rotor was assembled according to manufacturers’s 
instructions and pump system installed, tubing was sterilised by 
rinsing with 70% ethanol, then washed with PBS and non-specific 
binding of cells was blocked by 30min incubation of tubes with 
LSEC medium. Cells were pumped in at 16ml/ min and a rotor speed 
of (2500rpm, 24°C). 100ml of each cell fraction was collected 
increasing the speed successively to 22 and 28ml/ min (recovery of 
portal and periportal LSEC), 32ml/ min (mixed population 
containing LSEC and Kupffer cells) and 56ml/ min (Kupffer cells 
only). Cells were taken up in LSEC medium and seeded into Corning 
Cellbind® or collagen coated culture plates (0.8x106, 0.4x106 and 
0.15x106 per 24, 48 and 96 well plate, respectively). 
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3.2.3 Isolation of cell subsets by magnetic activated cell sorting (MACS) 
Material AutoMACS, MACS beads, MACS buffer 
Method Defined number of cells (manufacturer’s instructions) e.g. a mixed 
population of liver cells, is taken up in ice cold MACS buffer and 
MACS beads are added. Cells are incubated for 15min at 4°C to 
allow antigen specific binding. Cells are then centrifuged (300xg, 
5min, 4°C), filtered and isolated via AutoMACS cell separation 
system.  
 LSEC, 24µl CD146 MACS beads in 200µl buffer per organ 
 DC, 20µl CD11c MACS beads in 300µl buffer per organ 
 CD8+ T cells, 20µl CD8α MACS beads in 300µl buffer per organ 
3.2.4 Purification of splenic DC 
Material Syringe with 25G needle, metal filter, GBBS with 0.04% w/v 
collagenase, T cell medium 
Method Spleens are perfused in vitro using a syringe with GBBS 0.04% w/v 
collagenase and incubated for 30min at 37°C. The spleen is passed 
through a metal filter (mesh size 250µm) and centrifuged (10min., 
350xg, 20°C). Cells are then either stained for FACS analysis or DC 
are purified by MACS and subsequently cultured in T cell medium. 
3.2.5 Purification of T cells 
Material metal filter, nylon wool, T cell medium 
Method Spleens and lymph nodes are passed through a metal filter (mesh size 
250µm), centrifuged (10min, 350xg, 20°C) and taken up in T cell 
medium. Cells are then incubated for 60min at 37°C on a column 
(syringe containing nylon wool, blocked by PBS with 2% FCS). DC 
and macrophages will adhere to the wool, while T and B cells will 
not, the latter cells are carefully washed off the column with 37°C 
warm T cell medium. CD8α+ T cells are purified by MACS. 
3.2.6 Purification of whole cells from lung, thymus and lymph nodes 
Material metal filter, MACS buffer, ACK lysis buffer 
Method Respective organs are passed through a metal filter (mesh size 
250µm) and centrifuged (10min, 350xg, 20°C). Subsequently cells 
are filtered and ACK lysis buffer is added for 1min, before ending 
erythrocyte lysis by addition of FCS. Cells can then be stained for 
FACS analysis.  
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3.2.7 Preparation of bmDC 
Material Syringe, GM-CSF containing medium 
Method Bone marrow is recovered from the hind legs, which are cut close to 
the abdomen. Legs are stored in PBS and muscle tissue is removed. 
Bone marrow is flushed out with PBS using a syringe and the cell 
suspension is centrifuged at 300xg for 3 minutes. Supernatant is 
carefully aspirated and cells resuspended in warm GM-CSF 
containing medium, then they are seeded into Petri dishes. Cells are 
split after 3 days. They can be recovered for experiments on day 6-8.  
3.2.8 FACSorting of cells for ex vivo analysis 
Material FACSorter, MACS buffer, LSEC medium 
Method To obtain highly pure cell populations for comparative analysis ex 
vivo, LSEC and CD8α+ DC are purified by FACSorting. To assess 
ex vivo cross-presentation mice are injected with 1mg OVA i.v., 
45min after this initial injection a soluble fluorochrome labeled 
scavenger ligand such as OVA, AcLDL or BSA is i.v. injected. 
LSEC and DC are purified according to the conventional purification 
methods described before (LSEC by elutriation or CD146+ MACS, 
DC by CD11c+ MACS). DC are then stained with anti-CD8a and 
anti-CD3 antibodies to exclude T cells. CD8a+CD3-CD11c+ DC and 
CD8a-CD3-CD11c+ DC are FACSsorted. LSEC with high scavenger 
activity for fluorochrome ligands in vivo are sorted (this excludes 
macrovascular endothelial cells). Cells are directly sorted into 96 
well plates with defined cell numbers. B3Z T cells are then added for 
assessment of cross-presentation as described. 
3.2.9 Staining cells for flow cytometric analysis 
Material CantoII, LSRII, MACS buffer 
Method Cells are stained with saturating concentrations of fluorochrome-
labeled antibodies for 15min in MACS buffer on ice after blocking of 
antibody binding to FcγR using an anti CD16/32 (10µg/ml). Dead 
cells are excluded from analysis by Hoechst-33258 staining 
(10µg/ml). Measurements were conducted with an LSR II or Canto II 
and data were analysed using FlowJo software. 
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3.2.10 T cell proliferation assay in vitro 
Material CantoII, LSRII, CFSE, T cell medium 
Method For proliferation experiments, naïve primary CD8+ T cells are 
labelled with 1µM CFSE (10min at 37°C). The labelling reaction is 
stopped by addition of FCS. T cells are then cultured in T cell 
medium with OVA-pulsed LSEC or DC for 72h before CFSE-
dilution is measured by flow cytometry.  
3.2.11 Assessment of cross-presentation 
Material OVA, PD-10 column, ELISA kit, cell culture media, 
Glutardialdehyde 
Method LSEC or DC are pulsed with OVA in vitro for 30min to 4h. To 
examine the influence of inhibitors on cross-presentation, LSEC and 
DC are pre-incubated with the respective inhibitor 15min to 1h 
before OVA addition. If required for the experiment APC are fixed 
with 0.008% glutardialdehyde (3min, subsequent extensive washing 
is mandatory). For assessment of cross-presentation in vivo or ex vivo 
mice are injected with OVA i.v. or i.p.. The OVA used is purified of 
contaminating peptides by PD-10 column purification, performed 
according to manufacturer’s guide lines. OVA-specific CD8 T cells 
(B3Z T cell hybridomas or CD8+ OT-1 T cells) can be used for 
determination of cross-presentation. T cells are cultured together 
with APC over night and cross-presentation is determined by 
measuring the IL-2 release from T cells by ELISA. 
3.2.12 Priming and restimulation of T cells in vitro 
Material ELISA kit, Lymphocyte separation solution 
Method T cells are cultured in T cell medium with LSEC and DC in a 24 well 
plate, 1x106 T cells/ well. If OT-I or St35/42 T cells are used, APC 
are pulsed with antigen prior to co-culture. The culture is examined 
daily and the medium is partially replaced in case it is used up (turns 
yellow). DC/ T cell cultures are split on day 2. On day 4 or 5 T cells 
are recovered from cultures and viable T cells are purified by a 
lymphocyte separation gradient. T cells are taken up in 5ml T cell 
medium, transferred into a 15ml tube and are underlaid with 2ml 
lymphocyte separation solution, gradient is centrifuged at 1400g for 
10 min. T cells are recovered from the interface, washed and seeded 
into anti-CD3 antibody (10µg/ml) coated 96 flat bottom well plates 
at 1x105 cells/ well. IFN-γ and IL-2 release into supernatant was 
measured by ELISA after 16h. 
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3.2.13 Assessment of T cell cytotoxicity in vitro 
Material CantoII, LSRII, CFSE, Lymphocyte separation solution 
Method T cells are recovered from cultures on day 4 and viable T cells are 
purified by a lymphocyte separation gradient, as described in the 
section “Priming and restimulation of T cells in vitro”. To assess 
specific lysis of target cells by OT-I T cells, target RMA cells are 
loaded with 10µM S8L peptide, control RMA cells are kept in PBS, 
for 30min at 37°C. Subsequently cells are washed 3 times 
(centrifuged at 10min, 350xg, 20°C). Target and control cells are 
then labelled with 1µM and 0.1µM CFSE, respectively. T cells are 
incubated with a 1:1 mixture of target and control cells at different 
effector target ratios (e.g. E:T ratios of 50:1, 25:1, 1:1). After 4-5h 
cells are measured by FACS and specific kill is calculated as the 
reduction in CFSE high target cells compared to CFSE low control 
cells:  
% specific kill = 100x [1-(CFSEhigh/CFSElow)probe/(CFSEhigh/CFSElow)control].
3.2.14 Immunofluorescence imaging of cultured LSEC 
Material 12mm glass cover slides, 10% v/v collagen R solution, 4% (w/v) 
PFA, blocking buffer 
Method 12mm glass cover slides are placed in a 24 well plate (1 cover slide 
per well) and coated for 1h with 10% v/v collagen R in H2O. LSEC 
are seeded at a density of 0.8x106 cells per well in LSEC medium. 
Non-adherent cells are washed off on day 1. On day 2 LSEC are 
pulsed for 3-15 min with fluorochrome-labeled OVA (5µg/ml), BSA 
(5µg/ml) transferrin (10µg/ml) or AcLDL (2µg/ml) and subsequently 
chased for 0min-3h with medium, before fixation with 4% w/v PFA. 
Cells are permeabilised with 0.1% Triton and blocked with PBS 
containing milk powder (5% w/v), serum (1-5% v/v) and 0.1% 
Triton. Cells are then stained with specific antibody, if a combination 
of primary and secondary antibodies for detection is used, two 
consecutive staining steps are needed. Nuclei are visualized with 
DAPI (0.5µg/ml, 5min). During the complete staining process cells 
are kept at room temperature and for optimal distribution of 
antibody, cells are rocked on a rocking platform. 
Immunofluorescence analysis is performed with an IX71, IX81 or 
FV 1000 confocal microscope. To quantitatively determine 
colocalization an automated analysis with the ScanR software is 
performed (Olympus, Germany). 
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3.2.15 ELISA 
Material ELISA reader, ELISA plate, Coating buffer, blocking solution, 
substrate 
Method ELISA 96 well plate is coated with 50µl purified monoclonal 
primary antibody per well in alkaline coating buffer and incubated 
for 1h at 37°C. Free plastic is blocked with 1% BSA in PBS for 
30min. Plate is thoroughly washed and centrifuged upside down to 
dry completely. Supernatants and a cytokine dilution standard diluted 
1/3 are added to wells and incubated for 1h at 37°C. Plate is washed 
and the biotinylated polyclonal secondary antibody diluted in PBS is 
added (incubation, 1h at 37°C). Plate is washed again and peroxidase 
in PBS is added (incubation, 30h at 4°C). Finally the plate is washed 
and centrifuged upside down and a substrate is added. Measurement 
of colour reaction in ELISA reader, the standard curve is plotted as a 
sigmoid curve, as peroxides is an allosteric enzyme.  
3.2.16 Western Blot 
Material Electrophoresis chamber, semi-dry transfer unit, Sample buffer, SDS 
running buffer, transfer buffer 
Method Primary cells are purified and whole cell lysates are taken up in 
sample buffer containing 60mg/ml DTT. Samples are cooked for 
10min at 95°C. The protein concentration is determined using the 
BioRad DC protein assay and equal amounts are used for separation 
on appropriate SDS/ polyacrylamide gels. Gels are then blotted onto 
a Nylon-P membrane. After transfer of protein onto the membrane, 
the protein is detected by a specific primary antibody in TBS/ 
Tween-20 (0.1%) milkpowder (5%) 1h at 20°C, the primary antibody 
is diluted as found to function best. The membrane is washed and 
primary antibody is detected by a secondary antibody which is 
conjugated to horseradish peroxidase (HRP). Chemiluminescence is 
detected on X-ray film. To demonstrate loading of equal amounts of 
protein, membranes are stripped of antibody using a stripping buffer 
and can then be stained for a ubiquitous protein such as actin.  
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3.2.17 Calculation of OVA clearance 
Method Amount of fluorescent ligand in cells at various time points was 
measured by flow cytometry and calculated as mean fluorescence 
intensity. For each one, the value at 55min was normalised to 100%. 
Then an exponential function was fitted to the data of all experiments 
using nonlinear least squares, i.e. the function  was 
minimised with a numerical algorithm in the Matlab software by 
Mathworks. 
( )∑ − 2it xdeβ
3.2.18 Determination of cell numbers 
Method Cell suspensions are diluted by a factor of 10 in Trypan Blue solution 
and 10µl are applied to the Neubauer counting chamber. 
Determination of total cell number is performed by counting four 
large squares. Only viable cells (cells that are not stained by Trypan 
Blue) are counted. The total cell number is calculated by the formula: 
[ ] [ ] [ factorchamberdilutioncountednumbercell
ml
numbercelltotal 1000010
4
1 ××=⎥⎦
⎤⎢⎣
⎡ ]
3.2.19 Statistics 
The Student’s two tailed t test was used for the evaluation of both in vitro and in vivo 
experiments. Results are shown as mean + standard error of the mean (SEM), p-values 
<0.05 were considered significant, * = p<0.05, ** = p<0.01, *** = p<0.001. 
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4.1 Rapid scavenging of circulating antigen by organ-resident LSEC 
To investigate which cell population eliminated antigen circulating within the blood 
stream, cellular uptake of Alexa-647 labeled OVA in various organs following 
intravenous application was quantified. Blood-borne antigen was clearly present in 
hepatic cells, whereas only little antigen was taken up by cells in the spleen or lung and 
as expected almost no antigen uptake was observed into cells within peripheral lymph 
nodes or primary lymphatic tissues (Fig. 1a). Antigen-uptake by liver cells was far more 
efficient by at least two log steps compared to antigen uptake by cells in other organs 
(Fig. 1a). Confocal analysis of perfusion-fixed liver tissue revealed that hepatic cells 
lining the liver sinusoids were taking up circulating antigen (Fig. 1b, left).  
Antigen uptake was stronger in the periportal field than in the perivenous field (Fig. 1b, 
right), indicating that cells lining the sinusoids in the periportal field are more efficient 
in antigen uptake. This phenomenon has been described before by the group of Barberá-
Guillem who could show that increased antigen uptake in the periportal field was not 
due to better access to antigen, but a feature of periportal LSEC (Vidal-Vanaclocha et 
al., 1993a; Vidal-Vanaclocha et al., 1993b). 
To further characterise this highly efficient hepatic scavenger cell population in the, 
liver cells were purified 1 hour after intravenous antigen administration and stained with 
specific antibody. Antigen-positive cells were not CD11c+ (DC cell marker) or CD11b+ 
(macrophage cell marker), but instead were CD146+ (endothelial cell marker) (Schrage 
et al., 2008) (Fig. 1c). However, not all CD146+ cells showed pronounced scavenger 
activity (Fig. 1c) suggesting that microvascular liver sinusoidal endothelial cells (LSEC) 
rather than macrovascular hepatic endothelial cells were responsible for antigen-uptake 
from the blood-stream. Direct comparison of scavenger activity of LSEC with DC from 
liver and spleen revealed that LSEC contained far more Alexa 647-OVA after 
intravenous application (Fig. 1d). 
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Figure 1. Preferential uptake of circulating soluble antigen by scavenger cells in the 
liver. a) Alexa647-labeled OVA (4µg/mouse) was intravenously injected and cells from 
various organs were isolated after 1h for flow cytometric analysis (a and c) or livers were 
perfusion-fixed (4% PFA) and 80µm thick tissue slices were analyzed by confocal laser 
scanning microscopy, OVA Alexa 647 is stained in red, autofluorescent hepatocytes appear 
green in left figure (b). (c) Hepatic cells taking up OVA from the circulation were stained for 
various surface markers for phenotypical analysis by flow cytometry. (d) LSEC, splenic or 
hepatic DC were isolated from mice 1h after intravenous injection of Alexa647-labeled OVA 
(20 µg/mouse) and fluorescence was analysed by flow cytometry. 
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4.2 More pronounced cross-presentation by LSEC compared to DC 
The next question addressed was whether efficient antigen uptake also allowed LSEC to 
efficiently cross-present soluble antigen to CD8 T cells. Previously it has been shown, 
that LSEC cross-presented endocytosed OVA on H2Kb- MHC I molecules as 
demonstrated by positive staining with the H2Kb-SIINFEKL-specific antibody 25.D1-16 
(Limmer et al., 2000). This finding indicated that scavenger LSEC constitute a 
homogenous cell population with respect to the ability to cross-present soluble antigens.  
For the comparison of cross-presentation and priming capacity of LSEC and DC, an in 
vitro antigen dose titration experiment was performed. Similar numbers of DC and 
LSEC were pulsed with increasing concentrations of OVA protein and T cells of the 
B3Z hybridoma cell line or primary naïve CFSE labelled OT-I T cells were added, for 
the assessment of cross-presentation or priming, respectively. These experiments 
revealed that LSEC were more efficient than DC in cross-presenting soluble OVA to 
B3Z (Fig. 2a) and in priming naïve CD8 T cells for proliferation (Fig. 2b). The more 
prominent cross-presentation by LSEC was accompanied by more pronounced antigen-
uptake in vitro compared to bone marrow derived dendritic cells (data not shown).  
To further study the contribution of LSEC to cross-presentation of circulating antigen in 
vivo, a novel isolation procedure was developed, based on immuno-magnetic separation 
in combination with FACSorting of hepatic cells with high scavenging activity. This 
procedure yielded a purity of more than 99% for CD146+ scavenger receptor+ LSEC 
(Fig. 2c) and made it possible to unequivocally characterize cross-presentation mediated 
by LSEC in comparison to splenic CD8α+ DC ex vivo. CD8α+ DC have been shown to 
be the most important DC subset for cross-presentation of soluble antigen (den Haan et 
al., 2000; Pooley et al., 2001). Animals were challenged with 1mg OVA i.v. followed 
by a second injection 45 minutes later of a fluorochrome labelled scavenger ligand such 
as BSA or AcLDL. Mice were sacrificed 15 minutes after the second injection. CD146+ 
LSEC and CD11c+ splenic DC were isolated by AutoMACS positive selection. CD11c+ 
cells were further stained for CD8α and CD3, to exclude CD8α+ T cells. LSEC with 
high uptake of scavenger ligand and CD3−, CD8α+ and CD3−, CD8α− DC where 
directly sorted into 96 well plates and ex vivo cross-presentation to B3Z T cells was 
assessed. 
Clearly, LSEC showed more pronounced cross-presentation of systemically circulating 
antigen than splenic CD8α+ dendritic cells (Fig. 2d). As expected, splenic CD8α− 
dendritic cells did not show significant cross-presentation capacity (Fig. 2d). 
 41 
4 Results 
Figure 2. More pronounced early cross-presentation by LSEC compared to DC. a) 
LSEC or bone marrow-derived DC (bmDC) were incubated with different concentrations of 
soluble OVA in vitro for 1h, cultured with H-2Kb-SIINFEKL-specific CD8 B3Z T cells over night 
and cross-presentation was determined by measuring IL-2 release into the cell culture 
supernatant. b) LSEC and bmDC pulsed with different concentrations of OVA were 
incubated with CFSE-labelled naïve OVA-specific OT-I CD8 T cells and proliferation was 
determined on day 3 by CFSE dilution. c) CD146+ LSEC were isolated from Alexa647-OVA 
iv injected mice. CD146+ LSEC were FACSorted according to high OVA uptake and purity 
of the sorted cell population was determined by further in vitro incubation with Alexa488-
AcLDL (1µg/ml) followed by flow cytometric analysis for OVA and AcLDL-uptake. d) LSEC, 
CD8α+ or CD8a- splenic CD11c+ DC were isolated from mice iv injected 1h before with 
OVA (1mg) and equal numbers of cells were FACSorted into 96 wells for direct ex vivo 
comparison of cross-presentation to B3Z cells.  
4.3 
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Elimination of ovalbumin from LSEC is rapid in vivo, limiting the 
duration of cross-presentation 
To allow for efficient and continuous scavenging activity in LSEC, antigen uptake 
needed to be accompanied by rapid elimination. Therefore, I characterized how long 
LSEC would retain antigen that was given in a bolus injection via the intravenous route. 
Isolating cells at various time points after intravenous application of Alexa 647-labelled 
OVA, showed that fluorescence intensity in LSEC in vivo was maximal 1 hour post 
injection and then gradually declined with a half-life of approximately 6 hours (Fig. 3a). 
Detection of OVA by immuno-blotting from isolated LSEC confirmed the rapid uptake 
and turnover of antigen in this cell population (Fig. 3b). Importantly, rapid turnover of 
antigen in LSEC was accompanied by a decrease in cross-presentation 20 hours after 
the antigen-uptake in vivo, whereas no such decrease was observed for dendritic cells 
isolated from spleen (Fig. 3c). Taken together, these data demonstrated that LSEC are 
potent cross-presenting cells and that their scavenging activity with high antigen-
turnover restricts the duration of cross-presentation. 
 
Figure 3. Rapid turn-over of endocytosed antigen in LSEC limits duration of cross-
presentation in vivo. a) Mice were i.v. injected with Alexa 647-OVA (4 µg) and LSEC were 
purified at various time points after injection and analysed by flow cytometry. Maximal 
uptake of OVA by LSEC determined as increase in mean fluorescence intensity (MFI) was 
observed 1h after injection and was set to 100%. Decreased MFI observed in LSEC at later 
time points is expressed in relation to maximal MFI. The non-linear correlation coefficient 
of antigen-clearance from LSEC is 0.967 and the t1/2 is calculated to 6h. b) LSEC were 
isolated at different time points after iv antigen injection and intracellular antigen 
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concentrations were determined by western blot. c) Cross-presentation of LSEC ex vivo to 
B3Z cells was determined at 1h or 20h after i.v. OVA injection. n.d. denotes not detected. 
4.4 The mannose receptor is redundant for cross-presentation of OVA 
in LSEC 
Uptake of soluble antigen via the mannose receptor has been shown to determine cross-
presentation in DC and macrophages (Burgdorf et al., 2007; Burgdorf et al., 2008). 
LSEC expressed the mannose receptor at high levels both at the cell surface and in 
intracellular compartments (Fig. 4a and b). The mannose receptor also colocalized with 
endocytosed fluorochrome-labelled OVA in endosomal compartments (Fig. 4c).  
In contrast to DC, which strictly required expression of the mannose receptor for cross-
presentation of soluble OVA, LSEC from mannose receptor-knockout animals retained 
their ability to cross-present OVA in vitro indicating that the mannose receptor was not 
essential (Fig. 4d).  
However, dose titration experiments in vitro revealed that lack of mannose receptor 
expression diminished the ability of LSEC to initiate proliferation of naïve OT-1 T cells 
at low antigen concentrations (Fig. 4e). A contribution of the mannose receptor to cross-
presentation was also observed under limiting antigen concentration in vivo, as LSEC 
from mannose receptor-knockout compared to wild-type animals showed less cross-
presentation capacity ex vivo (Fig. 4f). Reduced cross-presentation was accompanied by 
reduced antigen uptake by mannose receptor deficient LSEC after intravenous OVA 
injection (Fig.4g). 
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Figure 4. The mannose receptor is not essential for cross-presentation in LSEC. a,b) 
LSEC were stained for surface (a) or intracellular expression (b) of the MR (CD206). c) 
Immunofluorescence microscopy of LSEC after endocytosis of fluorochrome-labeled OVA 
stained for the MR. d) LSEC from MR-/- and wt B6 were pulsed with OVA (1mg/ml) and 
cross-presentation to B3Z cells was measured by determination of IL-2 release by ELISA. e) 
Proliferation of CFSE-labeled naïve OT-I T cells 72h after priming by MR-/- or wt LSEC 
pulsed with different OVA concentrations; numbers denote division indices. f) Ex vivo cross-
presentation by MR-/- and wt LSEC 1h after i.v. injection of OVA (1 mg); mean of 5 
independent experiments is shown. g) Uptake of fluorochrome-labeled OVA by B6 or MR-/- 
or wt LSEC in vivo after i.v. injection of 4µg OVA, MFI is shown in brackets. 
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4.5 Unique antigen shuttling after receptor-mediated endocytosis in 
LSEC 
In macrophages and dendritic cells, uptake via different cell-surface receptors leads to 
delivery into distinct endosomal compartments that support either cross-presentation in 
case of the mannose receptor or MHC II-restricted presentation in case of the scavenger 
receptor (Burgdorf et al., 2007). LSEC apart from expressing the mannose receptor 
(Fig. 4a and b) also express other C-type lectin receptors like mSIGNR-1 and various 
scavenger receptors like the macrophage scavenger receptor-A (CD204) (Fig. 5a).  
In LSEC, uptake through the scavenger receptor (for AcLDL and BSA), mannose 
receptor (for OVA) or transferrin receptor (for transferrin) all resulted in delivery of the 
respective ligands into the same early endosomal compartment within several minutes 
(Fig. 5b) indicating the existence of a common endosomal trafficking pathway for such 
receptor-mediated endocytosis. The endosomal compartment was characterized as an 
early endosomal one by expression of the marker early endosomal antigen 1 (EEA1) 
(Fig. 5c). Colocalization of endocytosed antigen with late endosomal (Rab7+) or 
lysosomal compartments (LAMP1+) could not be detected for up to 3 hours after 
antigen uptake (Fig. 5d). Macropinocytosis did not contribute to cross-presentation as 
amiloride failed to influence antigen-uptake and cross-presentation in LSEC (data not 
shown, (Limmer et al., 2005), while blocking all receptor mediated uptake by a high 
dose of polyI completely blocked cross-presentation (Fig. 5e).  
In LSEC cross-presentation of OVA was rapidly achieved within 45 to 60 minutes after 
uptake (Fig. 5f) and (Limmer et al., 2000). Furtehrmore, OVA colocalized with EEA1+ 
compartments only at early time-points after receptor-mediated uptake, already 60 
minutes after antigen uptake, there was almost no colocalization of OVA and EEA1+ 
compartments visible (Fig. 5g).  
These findings suggested that the early endosomal compartment into which 
endocytosed OVA was initially delivered, was not stable over time. Further support for 
a continuous endosomal transport of endocytosed antigen in LSEC came from the 
observation that OVA taken up 45 minutes after a first OVA-challenge did not 
colocalize in early endosomal compartments with the OVA taken up earlier (Fig. 5h). 
Routing of antigen taken up by receptor-mediated endocytosis in LSEC is 
fundamentally different from that in dendritic cells or macrophages.  
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Figure 5. Unique routing of antigen in LSEC. a) Surface expression of the receptors 
mSIGNR1 and CD204 on LSEC ex-vivo. b) Endocytosed antigens colocalise in an early 
endosomal compartment in LSEC. LSEC were simultaneously incubated with differentially 
fluorochrome-labelled ligands for 15 min and directly fixed with glutardialdehyde. c) 
Immunofluorescence microscopy of LSEC after endocytosis of fluorochrome-labelled OVA 
or AcLDL stained for EEA1 or d) stained for Rab7 and LAMP1 3h after endocytosis. e) 
Abrogation of cross-presentation by poly-inosinic acid (polyI) in vitro. f) Colocalisation of 
OVA and EEA1 declines within 1h of antigen uptake, immunofluorescence microscopy of 
LSEC stained for the EEA1 1h after endocytosis of fluorochrome-labelled OVA, at different 
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time-points after endocytosis percent colocalisation was quantified. g) Immunofluorescence 
microscopy of LSEC after endocytosis of differentially labelled OVA given 45 minutes apart, 
percent colocalisation of differentially-labelled OVA is quantified for either simultaneous 
application or after separate applications. 
4.6 Molecular mechanisms determining cross-presentation in LSEC 
How do LSEC accommodate their scavenger and important clearance function with the 
ability to simultaneously cross-present soluble antigens? Firstly, endosomal 
acidification was required because cross-presentation in LSEC was prevented by drugs 
inhibiting vesicular ATPase such as bafilomycin (Fig. 6a) or chloroquine (data not 
shown).  
Proteasomal processing was absolutely required for cross-presentation (Fig. 6b) as was 
already reported by our group before (Limmer et al., 2000). The need for proteasomal 
degradation indicated that cross-presentation required transport of antigen from 
presumably the early endosomal compartment into the cytosol. Functional transporter 
associated with antigen processing (TAP) was also required for cross-presentation as 
incubation of LSEC with a TAP-inhibitor derived from EBV (BNLF2) (Hislop et al., 
2007) abrogated cross-presentation completely (Fig. 6c).  
However, we could not detect TAP within EEA1+ endosomes (Fig. 6d). This finding is 
in contrast to one made in DC, where the localisation of TAP to EEA1+ endosomes 
confers cross-presentation competence to this particular compartment (Burgdorf et al., 
2008). To further validate the independence of cross-presentation from peptide-loading 
of MHC I molecules within TAP containing endosomes, LSEC were pre-incubated with 
primaquine, a known inhibitor of endosomal transport to the cell surface, which 
abolished cross-presentation in dendritic cells (Burgdorf et al., 2007). Primaquine did 
not have a significant influence on cross-presentation in LSEC but inhibited cross-
presentation in DC (Fig. 6e). These findings indicate that apart from showing very 
distinct routing of endocytosed antigen, LSEC furthermore did not employ the same 
endosomal compartment for cross-presentation as did DC. 
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Figure 6. Mechanisms determining cross-presentation in LSEC. ELISA of IL-2 in 
supernatant of B3Z cells incubated with OVA-pulsed LSEC treated with bafilomycin (a), 
epoxomicin (b) or a TAP-inhibiting peptide, derived from EBV BNLF2a (c). d) 
Immunfluorescence microscopy of LSEC staining for TAP1 and OVA (upper panel) or TAP1 
and calnexin (lower panel). e) BmDC and LSEC treated with primaquine were pulsed with 
OVA and incubated with B3Z cells, % T cell activation was calculated from IL-2 release of T 
cells. For controls, LSEC were incubated with SIINFEKL-peptide and cross-presentation to 
B3Z cells was determined. Insets show peptide control (a, b and d) and solvent control (c). 
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4.7 Immune complexed antigens are inefficiently cross-presented by 
LSEC 
As cross-presentation was closely correlated to scavenging activity of LSEC, the 
possibility arose that antigen uptake through receptor-mediated endocytosis in general 
conferred the capacity of cross-presentation. To test this hypothesis, LSEC were pulsed 
with opsonized or immune complexed antigen. Immune complexed antigen is not taken 
up by scavenger receptors, but via Fcγ receptors (FcγR). Clearly, there was little uptake 
of fluorochrome-labelled antibodies compared to uptake of OVA (Fig. 7a) although 
LSEC expressed significant levels of FcγRII/III at the cell surface (Fig. 7b). 
Interestingly, FcγR-mediated antibody uptake was more pronounced in DC (data not 
shown) and has been reported to increase antigen-presentation (Nimmerjahn and 
Ravetch, 2008; Regnault et al., 1999).  
These results demonstrated that FcγR-mediated uptake of antibodies in LSEC was slow 
compared to uptake through C-type lectin or scavenger receptors. Importantly, there 
was no significant colocalization of endocytosed OVA and antibody taken up by FcγRII 
in LSEC (Fig. 7c), which suggested distinct endosomal routing. To investigate whether 
antigen-uptake via FcγR altered the ability of LSEC for cross-presentation, LSEC were 
incubated with different ratios of OVA to anti-OVA antibodies. If OVA-specific 
antibodies were in excess over OVA, I observed a reduction in cross-presentation by 
LSEC in vitro (Fig. 7d). Collectively, these results demonstrated that FcγR-mediated 
antigen uptake occurred with low efficiency and that antigen complexed to 
immunoglobulins was cross-presented less efficiently by LSEC.  
As LSEC are known to induce immune tolerance in naïve T cells, this observation could 
have important implications on the induction of a productive immune response in the 
presence of antibodies.  
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Figure 7. Reduced cross-presentation of immuncomplexed OVA. a) Flow cytometric 
analysis of uptake of Alexa 647-labeled OVA or Alexa 488-labeled rat IgG at several time 
points, MFI values at 30min are shown. b) Immunostaining for FcγRII/III on LSEC. c) 
Fluorescence microscopy of LSEC after incubation with Alexa-647 OVA and Alexa 488-rat 
IgG for 15 min. d) ELISA of IL-2 from supernatant of B3Z cells incubated with LSEC pulsed 
with OVA in the presence of different concentrations of anti-OVA IgG (OVA 100µg 
complexed to 600µg, 300µg or 75µg specific mouse anti OVA IgG). 
 
So far I could show that LSEC are highly efficient scavenger cells for soluble antigen, 
which are capable of cross-presenting antigens to CD8α+ T cells, utilising molecular 
mechanisms and kinetics distinct from DC. It has been shown by our group before that 
rather than inducing immunity, LSEC can tolerize naïve T cells, suppressing immune 
reactions towards the respective antigens (Limmer et al., 2000; Limmer et al., 2005). In 
order to mediate immune functions LSEC can present antigen on MHC I and MHC II 
molecules and express co-stimulatory and co-inhibitory molecules usually found only 
on professional antigen presenting cells such as DC and macrophages. LSEC combine 
strong cross-presentation with low delivery of co-stimulation via CD80/ 86, but high co-
inhibition via B7-H1 (PD-1 ligand) (Diehl et al., 2008). Thus LSEC can be classified as 
organ resident antigen presenting cells. 
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4.8 CD8α+ T cells tolerized by LSEC show no cytotoxicity and have a 
distinct phenotype compared to those activated by DC  
To investigate the functional outcome of antigen cross-presentation by LSEC to naïve 
CD8α+ T cells in comparison to activation by DC, naïve OVA specific CD8α+ OT-I T 
cells were cultured either with LSEC or DC cross-presenting OVA peptide. On day 1 
the activation marker CD69 was up-regulated on all T cells, showing that they had 
recognised cognate antigen. L-selectin (CD62L) which mediates exclusion from lymph 
nodes, was down-regulated upon activation, this was more pronounced on T cells 
cultured with DC. The high affinity IL-2 receptor α-chain (CD25) was up-regulated on 
T cells primed by DC and to a lesser extent by those primed by LSEC (Fig. 8a and 
(Diehl et al., 2008)).  
As priming by DC was always accompanied by the induction of IL-2 expression in 
naïve T cells, IL-2 release into the supernatant was measured at day 1. T cells cultured 
with DC had as expected released high amounts of IL-2. However, those cultured with 
LSEC did not release detectable IL-2 levels (Fig.8b). Albeit the quantitative difference 
in surface marker expression and IL-2 production, T cells primed by LSEC or DC 
showed no difference in proliferation on day 3 (Fig 8c). It has been described before 
that IL-2 has no direct effect on antigen driven T cell proliferation in vivo and in vitro 
(Kundig et al., 1993; Lantz et al., 2000).  
On day 4 T cells were recovered from the cultures by using a lymphocyte separation 
gradient, excluding dead and non lymphoid cells. Cells were again stained for 
expression of various surface markers. The activation marker CD44 that is continuously 
expressed after initial activation was equally high up-regulated on both T cell groups. In 
contrast CD25 was completely down-regulated on LSEC primed T cells, but remained 
high on DC primed ones, while CD62L was high on the first and low on the latter group 
(Fig 8d and (Diehl et al., 2008)). To examine the functional properties of LSEC or DC 
primed T cells, T cells were seeded into αCD3 coated wells over night and cytokine 
release was measured by ELISA. In contrast to the strong cytokine release by DC 
primed T cells, those primed by LSEC showed strongly impaired IFNγ and IL-2 release 
(Fig 8e, and previously shown in (Diehl et al., 2008; Limmer et al., 2000)). 
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Figure 8. Phenotype of LSEC tolerized and DC activated T cells. a) Surface marker 
expression on OT-I T cells at day 1 of co-culture with DC or LSEC, flow cytometric analysis 
and b) ELISA of IL-2 release. c) LSEC and DC are equally efficient in cross-priming of 
naïve CD8α+ T cells. Proliferation profiles of CFSE labelled OT-I T cells on day 3 after 
priming, flow cytometric analysis of CFSE dilution. d) Expression of various surface 
markers on day 4 of culture. T cells were purified and stained for FACS analysis. e) 
Restimulation of OT-I T cells in αCD3 coated wells on day 4 shows abrogation of effector 
cytokine production by LSEC primed T cells. Representative experiments are shown. 
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4.9 Exogenous IL-2 breaks tolerance induction by LSEC 
One of the main differences during priming of naïve CD8α+ T by LSEC was the 
absence of IL-2 production by the T cells (Fig 8b). It has been shown that IL-2 can 
overcome the induction of T cell anergy (Dure and Macian, 2009). To test whether in 
vitro addition of IL-2 to LSEC/ T cell culture would break the induction of LSEC 
mediated tolerance, exogenous IL-2 was added in different concentrations during onset 
of the culture. Addition of exogenous IL-2 slightly increased the surface expression of 
the high affinity IL-2 receptor α-chain, measured on day 1, although not to the 
expression level reached by T cells primed by DC (Fig 9a). T cells were recovered on 
day 4 and again restimulated in αCD3 coated wells. IFNγ production was then 
measured as an indicator for activation.  
T cells cultured with LSEC in the presence of exogenous IL-2 showed IFNγ production 
upon restimulation which was comparable to T cells activated by DC (Fig 9b). To 
ascertain that T cells primed by LSEC in the presence of IL-2 had developed full 
effector functions an in vitro kill experiment was performed, measuring antigen specific 
kill of S8L pulsed target cells. T cells primed in the presence of IL-2 showed strong 
cytotoxic activity, which strength was directly correlated to the amount of IL-2 added 
during priming (Fig. 9c). Clearly these results show that IL-2 breaks tolerance induction 
by LSEC. 
 
Figure 9. Influence of exogenous IL-2 on T cell priming by LSEC. a) Surface expression 
of CD25 (day 1) on T cells primed in the presence or absence of exogenously added IL-2, 
flow cytometric analysis and b) restimulation on αCD3 (day 4). c) Representative in vitro 
kill experiment, T cells were purified from cultures on day 4 and specific lysis of S8L pulsed 
target cells was measured by FACS analysis and calculated as % kill. 
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4.10 Intrinsic IL-2 production of T cells receiving a strong signal 1 
through LSEC leads to effector cytokine production  
While OT-I T cells primed by LSEC at 0,01mg- 0,1mg OVA/ml acquired a tolerant 
phenotype, I made the observation that T cells primed by LSEC at higher antigen 
concentrations (OVA 1mg/ml) were capable of producing comparable amounts of the 
effector cytokines IL-2 and IFNγ to DC activated T cells when restimulated at day 4 
(Fig 10a). These findings suggested that a strong signal 1 delivered by the highly 
efficient cross-presentation mediated by LSEC could induce the production of IL-2 by T 
cells during priming, leading to the suppression of tolerance induction.  
To test this hypothesis LSEC were pulsed with different OVA concentrations, starting at 
1mg/ml and IL-2 release into the supernatant was measured at day 1. Indeed naïve OT-I 
T cells being primed by LSEC at high antigen concentrations produced significant 
amounts of IL-2 (Fig. 10b). When examining the surface expression of these LSEC 
activated T cells on day 4, T cells having received a very strong signal 1 maintained 
high CD25 expression in comparison to tolerized T cells (Fig 10c). However, in contrast 
to those activated by DC, LSEC primed T cells, showed no CD62L decrease (Fig 10c). 
Signalling via CD80/86 to CD28 on the T cells enhances the shedding of CD62L. This 
can be demonstrated through priming by CD80/86 deficient DC in which case CD62L 
surface expression on T cells remains high (data not shown).  
To validate that the activation of T cells did indeed result from intrinsic IL-2 production 
upon strong activation via the TCR, an IL-2 blocking antibody was added to the LSEC/ 
T cell co-culture at 1mg/ml OVA. T cells which received a strong signal 1 but no longer 
a signal via IL-2, resembled tolerized T cells and failed to produce IFNγ or IL-2 upon 
restimulation (Fig.10d and data not shown).  
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Figure 10. Influence of T cell derived IL-2 on tolerance induction by LSEC. a) T cells 
were primed by LSEC at different OVA concentrations and restimulated at day 4. T cells 
primed at 1mg/ml OVA produced effector cytokines, measured by ELISA. b) Significant 
intrinsic IL-2 production by LSEC primed T cells at day1 at high OVA concentration 
(ELISA). c) Flow cytometric analysis of surface marker expression on day 4 after priming. d) 
Blocking IL-2 by a specific antibody rescues tolerance induction even at high OVA 
concentrations resulting in abrogation of IFNγ production, ELISA after restimulation on day 
4. 
4.11 Susceptibility to activation via signal 1 depends on T cell receptor 
avidity 
OT-I T cells are known to express a relatively high number of T cell receptor (TCR), 
conferring a high avidity towards their MHC I cognate antigen complex suggesting that 
they were readily activated. Would T cells that expressed only low amounts of TCR 
therefore be inert to reacting to a high number of peptide MHC class I molecules 
presented to them?  
To this end LSEC or DC were cultured with naïve CD8+ T cells derive from the St35 
mouse strain, which recognise an adenovirus E1a protein derived peptide with the 
sequence SGPSNTPPEI (SGP) in the context of H2Kb. St35 T cells have approximately 
5 fold reduced TCR expression compared to OT-I T cells (Fig 11a). DC and LSEC were 
pulsed with high concentrations of SGP and washed thoroughly before St35 T cells 
were added. However, St35 T cells could not be induced to produce IL-2 at day 1 when 
primed by LSEC even at high antigen concentrations (Fig 11b), which was easily 
achieved using OT-I T cells cultured with S8L pulsed LSEC (data not shown). 
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Furthermore, St35 T cells only produced IL-2 or IFNγ upon restimulation when cultured 
with DC but never after culture with LSEC. However if exogenous IL-2 was added to 
LSEC cultures during priming, St35 T cells were activated and produced effector 
cytokines when restimulated (Fig. 11c). The weak activatory TCR signal received due 
to the low avidity of St35 TCR was also evident in the overall reduced cytokine 
production compared to OT-I T cells.  
 
Figure 11. Influence of TCR avidity on T cell activation. a) TCR surface expression was 
measured by staining with TCRβ specific antibody, flow cytometric analysis. b) IL-2 
production by naive St35 CD8α+ T cells on day 1 of co-culture of SGP pulsed DC and 
LSEC. c) Amount IFNγ produced by St35 T cells during restimulation (day 4) measured by 
ELISA. 
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4.12 LSEC delivering a strong signal 1 to T cells do not induce 
cytotoxicity 
Surprisingly, albeit the high amount of effector cytokines produced during restimulation 
by OT-I T cells which had received a strong signal 1 by LSEC, these T cells showed no 
cytotoxicity towards target cells carrying the cognate antigen (Fig 12a). The reason for 
this discrepancy between effector cytokine production especially IFNγ and cytotoxic 
function could result from the low signalling via co-stimulatory molecules (CD80/86) 
and absence of signal 3 as LSEC do not produce IL-12 in combination with high 
expression of the co-inhibitory molecule B7-H1 on LSEC (Diehl et al., 2008).  
The co-inhibitory molecule B7-H1 is upregulated on LSEC in response to antigen 
specific interaction with T cells (Diehl et al., 2008). Furthermore the increase in B7-H1 
expression on LSEC is directly correlated to the amount of antigen presented by LSEC 
and therefore to the strength of T cell/ LSEC interaction (Fig. 12b). 
 
Figure 12. T cells primed by B7-H1 sufficient LSEC lack cytotoxicity. a) Specific kill of 
S8L pulsed target cells on day 4 of culture. b) B7-H1 is upregulated on LSEC upon cognate 
interaction with OT-I T cells. LSEC were pulsed with different OVA concentrations, purified 
1 day after culture onset and stained for B7-H1 surface expression for flow cytometric 
analysis. 
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4.13 B7-H1 counteracts IL-2 production by T cells during priming, 
inhibiting full T cell activation 
B7-H1 is vital in the induction of T cell tolerance by LSEC, as B7-H1 deficient LSEC 
did not induce tolerance, but on the contrary fully activated naïve CD8+ T cells (Diehl 
et al., 2008). During priming by B7-H1 deficient LSEC, IL-2 production by T cells was 
dramatically increased compared to wt primed T cells even at low antigen 
concentrations where the signal delivered via the TCR is weak (Fig 13a). However IL-2 
production was not independent of TCR signal strength as reducing antigen 
concentrations led to reduced IL-2 production (Fig 13a).  
T cells primed in the absence of B7-H1 showed strong expression of CD25 (Fig 13b) 
resulting in an increased sensitivity to IL-2, thereby further promoting activation. Upon 
restimulation these T cells produced high amounts of effector cytokines (Fig 13c and 
(Diehl et al., 2008)). Furthermore, in contrast to T cells which had been activated by 
wild type LSEC delivering a strong signal 1 but simultaneously co-inhibitory signals via 
B7-H1, T cells activated by LSEC in the absence of B7-H1 showed full cytotoxic 
activity (Fig 13d and (Diehl et al., 2008)). 
However activation of T cells through B7-H1 deficient LSEC absolutely depended on 
the presence of IL-2. When IL-2 blocking antibodies were applied to the culture 
medium during priming, T cell activation was completely inhibited, resulting in 
abrogation of effector cytokine production and cytotoxicity (Fig 13e). These results 
strongly support the notion that B7-H1 supports the induction of tolerance in naïve 
CD8+ T cells via the inhibition of IL-2.  
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Figure 13. B7-H1 is vital for tolerance induction and mediates its effect via suppressing 
IL-2 production by T cells. a) Priming by B7-H1 deficient LSEC leads to strong IL-2 
production by T cells on day 1 as measured by ELISA. b) CD25 remains highly expressed on 
T cells primed by B7-H1 deficient LSEC, Flow cytometric analysis of surface stain on day 4. 
c) IFNγ release by T cells during restimulation is increased if B7-H1 is missing on LSEC 
during priming, day 4, ELISA. d) T cells primed by B7-H1 show strong cytotoxic activity. 
Evaluation of specific cytotoxicity on day 4. e) Induction of effector cytokine production and 
cytotoxicity by B7-H1 deficient LSEC is dependent on the presence of IL-2 during priming. 
Left diagramshows IFNγ production after restimulation and right diagram shows specific 
kill of target cells, ELISA and analysis by flow cytometry, respectively, both on day 4. 
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5.1 Hepatic immune functions 
The liver has important clearance and metabolic functions. Portal venous blood 
reaching the liver is mainly derived from the gut (Knolle and Gerken, 2000) and is very 
rich in non self proteins derived from food and bacterial products mostly from 
commensal bacteria. The liver is endowed with the capacity to modulate immune 
responses in order to educate immune cells not to attack cells presenting harmless 
antigen in the periphery, therefore protection of hepatocytes is vital. 
The hepatic microanatomy is formed to support this dual function. LSEC are located at 
the interface between cells of the immune system e.g. naïve but also activated 
lymphocytes and leukocytes travelling through the sinusoids and clearance and 
metabolism of antigen by hepatocytes. Therefore LSEC play a pivotal role in shielding 
hepatocytes from direct contact with passenger immune cells, inducing tolerance in 
naïve T cells, but also transferring antigen for metabolism and clearance by hepatocytes 
and finally fulfilling sentinel functions during infection of the liver (Billiar et al., 1992; 
Knolle et al., 1997). The clearance of host derived waste products like collagens 
(Malovic et al., 2007), bacterial degradation products and clearance of apoptotic cell 
fragments is an important function of the so called reticuloendothelial system that is 
comprised of Kupffer cells and LSEC (Knolle and Gerken, 2000). Antigen eliminated 
from LSEC is most likely transferred to hepatocytes for secretion via the bile in a 
process called transcytosis, because initially i.v. injected OVA could be detected in 
gallbladder bile at later time points (data not shown). Especially bacterial products 
contained within the venous blood from the gut would elicit strong immune responses if 
they reached the systemic circulation, therefore their clearance is vital to the organism’s 
well-being (Knolle and Gerken, 2000). On the other hand such transcytotic transport 
across LSEC may for some viruses facilitate targeting of hepatocytes, as our group and 
others have recently reported (Breiner et al., 2001; Gardner et al., 2003).  
5.2 Rapid uptake of blood borne antigen by LSEC 
While performing their clearance function, LSEC simultaneously process endocytosed 
antigen for subsequent presentation on MHC class II to CD4+ and cross-presentation on 
MHC class I to CD8+ T cells for the induction of tolerance under homeostatic 
conditions (Limmer et al., 2000). Here I investigated the distribution of soluble systemic 
antigens. After i.v. injection of fluorochrome labelled OVA, cells of the liver sinusoids 
were found to show most prominent uptake (Fig 1 b). These cells were isolated and 
clearly identified as LSEC. No other cell population within the liver showed comparable 
uptake of soluble antigen. Furthermore no comparably efficient scavenger cell 
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population could be detected in other organs (Fig 1a), which strongly suggests that 
LSEC are the main scavenger cell population for clearance of soluble antigen in the 
body.  
5.3 LSEC show more pronounced cross-presentation than DC 
To investigate antigen presentation capacity of LSEC and splenic CD8α+ DC from 
OVA injected mice were isolated. For unequivocal comparison of the ex-vivo cross-
presentation capacity by the two cell populations, cells were highly purified by 
FACSorting. As only LSEC were found to efficiently take up soluble ligands in the 
liver, was i.v. injected. Highly scavenger ligand positive, CD146+ LSEC were then 
sorted, excluding contaminating DC, KC and macrovascular LEC which do not show 
scavenger activity (Knolle and Limmer, 2003). Splenic DC which were CD11c+ CD8α+ 
and CD3- to exclude CD8+ T cells were also FACSorted.  
CD8α+ DC have been described to be the most efficient DC population responsible for 
cross-presentation of soluble antigens to CD8+ T cells (den Haan et al., 2000; Pooley et 
al., 2001). However, I found that at a per cell basis LSEC showed better cross-
presentation to CD8+ T cells ex vivo than splenic CD8α+ DC. In line with the ex vivo 
finding, antigen uptake and cross-presentation by LSEC in vitro was also superior to 
DC as revealed by antigen dose titration experiments. Even priming of naïve CD8+ T 
cells and induction of proliferation, which requires additional signalling through 
costimulatory molecules (Frauwirth and Thompson, 2002; Nurieva et al., 2006), was 
more efficiently performed by LSEC than by DC at limiting antigen concentration. 
Rapid antigen-specific adhesion of naïve CD8+ T cells, which is exclusively observed in 
the liver but not in secondary lymphatic tissue and is mediated by cross-presentation of 
circulating antigen by LSEC (von Oppen et al., 2008) supports the notion that cross-
presentation of circulating antigens by LSEC in vivo is at least as prominent as cross-
presentation by DC. Although cross-presentation by LSEC is stronger at early time 
points than cross-presentation by DC ex vivo and in vitro, it is important to note that 
LSEC take up far more antigen to achieve such strong presentation. It therefore seems 
that utilisation of antigen by DC is more efficient as in relation to the amount of antigen 
taken up cross-presentation was higher.  
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5.4 Distinct kinetics of antigen clearance and cross-presentation in 
LSEC 
LSEC and DC show strong differences in their cross-presentation kinetics. As discussed 
before soluble antigen which was given in a bolus injection was found to be rapidly 
taken up by LSEC. The concentration of antigen in LSEC was found to be highest 1h 
post injection. In order to maintain continuous scavenger activity LSEC need to clear 
antigen efficiently. Indeed, endocytosed antigen was cleared with a half life of only 6hrs 
from LSEC in vivo, whereas antigen taken up by DC was observed to be maintained in 
these cells over a long period of time (Faure et al., 2009).  
Rapid clearance of antigen from LSEC was accompanied by a decline in cross-
presentation. Thus cross-presentation of the injected antigen was reduced in LSEC by 
more than 70% within 20h while in DC presentation remained stable during the same 
time period (Fig.3a). For DC one of the mayor functions is to sense the presence of 
pathogens and in response induce immunity in T lymphocytes. DC mature upon antigen 
encounter in combination with a danger signal from a tissue resident, strongly 
phagocytic cell with low antigen presenting capacity into a weakly phagocytic but 
efficient antigen presenting cell (Banchereau and Steinman, 1998; Palm and Medzhitov, 
2009). After having taken up antigen and thereupon being activated, DC travel to LN in 
order to meet cognate T cells in a specialized microenvironment facilitating contact 
between antigen-presenting DC and T cells. It has recently been shown that DC did not 
prime T cells when in contact with tissue cells like LSEC or fibroblasts (Schildberg et 
al., 2008). This suggeststhat activation of T cells by DC can only take place in 
lymphatic organs. Once reaching the lymph nodes DC might have to persist for some 
time until encountering T cells expressing receptors recognizing the presented antigen, 
as this presumably might take some time, the time window for cross-presentation must 
be extended to facilitate induction of T cell responses.  
In contrast, LSEC do not need to undergo maturation in order to efficiently present 
antigen (Knolle and Limmer, 2003). Furthermore as sessile cells they do not move to 
lymph nodes to interact with lymphocytes, but can prime T cells within the hepatic 
microenvironment. However, the entire blood volume moves through the liver more 
than 300 times a day (Knolle and Limmer, 2003) carrying about 108 peripheral 
lymphocytes (Racanelli and Rehermann, 2006), facilitating fast encounter of LSEC and 
potentially reactive T cells present in the circulation. Presumably most circulating 
antigens taken up by LSEC are also presented. As the duration for presentation of a 
given antigen is short, it can be hypothesized that tolerance is induced only towards 
antigens which are continuously circulating. Foreign antigens which are only present for 
a short time or at low concentrations might not be presented, therefore, T cells most 
likely remain ignorant.  
Antigens which are present for prolonged time could either be derived from self in 
which case peripheral tolerance is induced or derived from a persistent infection, in 
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which case tolerance induction by LSEC would contribute to manifestation of chronic 
disease. Indeed many pathogens with liver tropism can cause chronic infections e.g. 
HBV and HCV. 
5.5 The mannose receptor is not essential for cross-presentation in 
LSEC 
Recently, it has been published by Burgdorf et al that in DC and macrophages cross-
presentation of soluble OVA is dependent on the expression of the mannose receptor. 
The mannose receptor facilitates cross-presentation by delivery of OVA into a stable 
early endosomal antigen 1 (EEA1) positive compartment where antigen loading onto 
MHC I molecules occurs (Burgdorf et al., 2007). Mannose receptor negative DC and 
macrophages were not able to cross-present OVA.  
LSEC express higher amounts of the mannose receptor on the surface and 
intracellularily than do DC, therefore the importance of the mannose receptor for cross-
presentation in LSEC was investigated. In contrast to the situation in DC and 
macrophages in LSEC the mannose receptor is redundant for cross-presentation. 
Mannose receptor deficient LSEC could cross-present soluble OVA ex vivo and in vitro. 
However, the mannose receptor does seem to contribute to cross-presentation as became 
apparent at limiting antigen concentrations, where antigen presentation was reduced in 
the absence of the mannose receptor.  
5.6 LSEC show distinct routing of antigen for cross-presentation 
The observation that the mannose receptor on LSEC was not essential for cross-
presentation of soluble antigen suggested the utilization of additional receptors. Blood 
passing through the liver is rich in foreign antigens, derived from food and bacteria and 
it might therefore not be sufficient to rely on a single receptor for cross-presentation and 
cross-tolerance induction. LSEC express a whole array of different scavenger and C-
type lectin receptors such as mSIGNR1, the murine functional homologue of human L-
SIGN (Koppel et al., 2005), which can also bind OVA. All of these receptors have been 
shown to efficiently internalize bound cargo (Lovdal et al., 2000).The employment of 
several receptors for cross-presentation could allow the induction of tolerance towards a 
greater range of antigens.  
To investigate the involvement of different endocytic receptors in cross-presentation in 
LSEC, intracellular routing of several ligands was analyzed. Burgdorf et al. could show 
a strict spatial separation for mannose-receptor mediated delivery into an EEA1+ 
compartment for cross-presentation or pinocytosis and scavenger-receptor-mediated 
delivery into lysosomal compartments for MHC class II restricted presentation in DC 
and macrophages, respectively (Burgdorf et al., 2007; Burgdorf et al., 2008). In LSEC, 
however, ligands of the mannose receptor, scavenger receptor and transferrin receptor 
were all rapidly delivered into a common endosomal compartment. This compartment 
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was also EEA1+. Clearly, in LSEC receptor mediated uptake is mandatory for cross-
presentation, as cross-presentation of soluble antigen was completely abrogated when 
blocking all receptor mediated uptake by poly-inosinic acid (polyI). PolyI has no 
influence on pinocytosis (data not shown), confirming the finding that pinocytosis is not 
involved in cross-presentation in LSEC (Limmer et al., 2005). This is in line with the 
finding, that antigen taken up via pinocytosis DC is located to lysosoms (Burgdorf et al., 
2007).  
In DC the early endosomal compartment dedicated to cross-presentation has been 
reported to be stable for several hours (Burgdorf unpublished observation). In contrast 
the early endosomal compartment in LSEC was not stable, but nearly completely lost 
the early endosomal marker EEA1 within 1h. Furthermore if two ligands were given at 
different time points they did not colocalize within the early endosomal compartment. 
These findings suggest that development of endosomes in LSEC is highly dynamic and 
might indicate endosomal movement through the cell. Endosomes in LSEC possibly 
carry cargo for transcytosis, quickly eliminating antigen. 
DC on the other hand have been reported to cross-present antigen upon maturation by a 
danger signal, which was taken up 48h previously, clearly showing that DC can 
sequester antigen for later presentation (Delamarre et al., 2003). 
5.7 Molecular mechanisms of cross-presentation in LSEC 
My studies showed that in contrast to DC, LSEC employ the mannose and scavenger 
receptors to shuttle antigen into early endosomal compartments for subsequent cross-
presentation. Acidification of this endosomal compartment is required, as the inhibitors 
of vacuolar H+ ATPase bafilomycin and chloroquine abrogate cross-presentation in 
LSEC. Possibly acidification is only mild, as endosomes have been described to have a 
weakly acidic pH (Burgdorf and Kurts, 2008). Endocytosed antigen does not localize to 
lysosomal compartments for at least 3h in LSEC, while cross-presentation can be 
detected as early as 30min after antigen uptake. These observations are in line with the 
finding that fusion of endosomes with lysosomes destroys antigenic peptides for MHC 
class I cross-presentation (Burgdorf and Kurts, 2008). Cross-presentation in LSEC is 
most likely initialized from the early endosomal compartment as antigens not routed 
into this compartment are badly cross-presented as will be discussed later.  
From endosomes antigen is exported into the cytosol by an unknown mechanism. 
Recently it has been shown, that transport of antigen into the cytosol involves 
components of the ER-associated degradation system (Ackerman et al., 2006; Wiertz et 
al., 1996) which might also be operative in LSEC. After delivery into the cytosol, 
antigen is processed by the proteasome, as shown by inhibition of the proteasome with 
epoxomicin, leading to complete abrogation of cross-presentation (shown here and by 
(Limmer et al., 2005)). In myeloid DC cross-presentation of exogenous soluble antigen 
is also dependent on the proteasome (Burgdorf et al., 2008).  
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Subsequent to proteasomal processing in the cytosol, antigen-derived peptides are 
reintroduced into early endosomes in DC. To this end the transporter for antigen 
processing (TAP), a usually ER-associated heterodimeric peptide transporter (Neefjes 
and Momburg, 1993) is recruited to endosomes for re-import of peptides from cytosol 
and loading onto MHC class I molecules within the endosome. I found no evidence in 
LSEC that peptides are reintroduced into the original early endosome after processing 
by the proteasome. TAP was detected in the ER where it colocalized with calnexin but 
not in endosomes colocalizing with either EEA1 or endocytosed OVA. As endosomes 
in LSEC were only transiently EEA1+ and not stable, this highly dynamic development 
of vesicles might not support loading within the endosomal compartment.  
TAP recruitment to stable early endosomes in DC occurs in response to danger signals 
such as LPS (Burgdorf et al., 2008) and thus reinforces cross-presentation of antigens 
that are associated with danger signals. In LSEC no TAP recruitment to endosomes 
even after exogenous addition of LPS could be observed (data not shown). However 
TAP is involved in cross-presentation of OVA in LSEC as blocking TAP with an 
inhibitor derived from the Ebstein-Barr virus (EBV) BNLF2a protein prevented cross-
presentation. BNLF2a binds to the cytosolic portion of TAP (Hislop et al., 2007) and 
therefore binding to TAP located in the ER or any other membrane cannot be 
distinguished.  
The ER distribution in LSEC is extensive (data not shown) which potentially could 
facilitate fast peptide import. The half-life of peptides within the cytosol is very short as 
they are quickly broken down by peptidases (Reits et al., 2003). Transport of soluble 
protein into the ER and MHC I loading at this site has been observed in DC (Ackerman 
et al., 2005). Another hint for the involvement of the ER or ER-derived components 
comes from the observation that cross-presentation in LSEC can be blocked by 
brefeldin A, which inhibits transport from the ER to the Golgi. Furthermore primaquine 
which inhibits endosomal recycling abrogates cross-presentation in DC, but has only 
little influence on cross-presentation in LSEC. The sensitivity to brefeldin A but not 
primaquine strongly suggests that there is no endosomal cross-presentation 
compartment in LSEC. However, it should be noted that primaquine is toxic to LSEC at 
higher concentrations (data not shown) indicating that endosomal recycling is a very 
important mechanism in these cells, even if not involved in cross-presentation.  
It has been shown that presentation of antigen on MHC class I molecules is highly 
inefficient. Only 0,1% of specific peptides, approximately, survive intracellular 
processing and can be loaded on MHC class I molecules (Yewdell et al., 2003). The 
extraordinary scavenging activity of LSEC could compensate for the lack of a 
specialized endosomal compartment incorporating antigen loading for cross-
presentation, but instead allow the utilisation of a less selective molecular mechanisms 
such as loading in the ER. However, even if antigen loading is not achieved within the 
early endosomal compartment in LSEC, receptor mediated shuttling towards it still 
66 
 5 Discussion 
determines entry of antigens into the cross-presentation pathway as will be discussed in 
the following.  
5.8 LSEC cross-presented immune complexed antigen only weakly  
To investigate whether all receptor mediated uptake resulted in routing of the ligand 
into the early endosomal compartment targeted by scavenger, mannose and transferrin 
receptor, antigen was incubated with specific antibody to allow uptake via FcγR. 
Antigens taken up by FcγR in LSEC did not colocalize with scavenger or mannose 
receptor ligands. Furthermore, they were not transferred into an EEA1 or transferrin 
positive compartment, showing that they were not localized to an early endosomal 
compartment. Although LSEC strongly expressed FcγRII and III on the surface, FcγR-
mediated uptake of antibodies was much lower compared to uptake of OVA or AcLDL. 
Most importantly in the presence of excess antibodies to OVA cross-presentation was 
reduced. In addition to demonstrating that most efficient endocytosis and cross-
presentation is not a uniform feature of all endocytic receptors in LSEC these findings 
also suggest that antigens, which have already elicited an CD4 T cell and B cell 
response leading to antibody production, will not be cross-presented by LSEC.  
As LSEC are known to induce tolerance towards their cross-presented antigen in T 
cells, reduced or absent cross-presentation of opsonized antigen is an intriguing possible 
mechanism to avoid the induction of tolerance towards an antigen which is targeted by 
an ongoing immune response. Lack of cross-presentation by LSEC may instead 
passively support induction of CD8 T cell immunity, helping to combat infection. On 
the other hand the strong bias of LSEC to induce tolerance could facilitate evasion 
mechanisms of pathogens. Hepatitis B virus is known to produce extensive amounts of 
virus antigens (Lopes et al., 2008) which if not opsonized sufficiently could lead to the 
induction of chronic hepatitis supported by tolerance inducing LSEC. 
5.9 Functional outcome of LSEC mediated cross-presentation 
As the functional outcome of efficient cross-presentation by LSEC is of major 
importance in health and disease, it’s study has been further pursued. The phenotype of 
CD8+ T cells having been primed by immunogenic DC or tolerogenic LSEC in vitro is 
distinct. Early during priming both groups show similar up-regulation of the high 
affinity IL-2 receptor (CD25) and the activation marker CD69, which allows retention 
of T cells within LN (Shiow et al., 2006). T cells primed by either, DC or LSEC, show 
proliferation undergoing several rounds of division indistinguishable in magnitude. 
However, those primed by LSEC cease to proliferate after approximately 72h (Diehl et 
al., 2008). The halt in proliferation is not followed by induction of apoptosis. T cells 
primed by LSEC have been shown to be positive for the anti-apoptotic molecule Bcl-2 
and additionally they expressed the low affinity IL-2 receptor (CD122) and the IL-7 
receptor (CD127) further aiding the survival of tolerant T cells (Diehl et al., 2008). This 
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indicates that tolerized T cells can persist. The IL-7 receptor is implicated in the 
survival of virus specific T cells during chronic hepatitis B infection (Lopes et al., 
2008).  
T cells acquiring a tolerant phenotype will eventually express low CD69 (not shown) 
and CD25 and high CD44 and L-selectin (CD62L) excluding them from leaving the 
blood to home to LN (Henrickson et al., 2008). When restimulated by triggering TCR 
signalling via targeting CD3 with a specific antibody, T cells tolerized by LSEC will not 
respond with effector cytokine production. This is in contrast to DC activated T cells 
which produce high amounts of IL-2 and IFNγ. Furthermore, T cells primed by LSEC 
do not exhibit cytotoxicity towards antigen presenting target cells (Diehl et al., 2008; 
Limmer et al., 2000). The lack of cytokine production and specific cytotoxicity is not 
caused by insufficient priming through LSEC, as continued high expression of CD44 on 
the whole population confirms that all T cells have encountered their cognate antigen 
(Diehl et al., 2008)  
5.10 IL-2 can break tolerance induction in naïve CD8+ T cells by 
LSEC 
IL-2 has been shown to mediate important immune functions, supporting clonal 
expansion and sustained T cell responses as well as functioning as a survival signal for 
regulatory T cells (D'Souza and Lefrancois, 2003). Furthermore IL-2 can overcome the 
induction and reverse established T cell anergy (Dure and Macian, 2009). Therefore IL-
2 can play a dual role supporting immune activation and termination.  
To investigate the influence of IL-2 during priming by LSEC, cultures were 
supplemented with exogenous IL-2. Addition of the exogenous cytokine broke tolerance 
induction by LSEC and led to full T cell activation in vitro. However, the strength of 
activation absolutely depended on the amount of exogenously added IL-2. While low 
IL-2 concentrations resulted in mild cytokine production and weak cytotoxic activity, 
both features could be increased with increasing IL-2 concentrations. This shows that 
IL-2 signalling is dynamic resulting in different levels of T cell activation, depending on 
the original signal strength. Could tolerance induction therefore be a result of low 
amounts or absent IL-2 during priming? 
Indeed, a clear difference during the first 24h of priming by LSEC or DC is seen in the 
production of IL-2 by T cells. T cells primed by DC secreted significant amounts of IL-
2, while when primed by LSEC IL-2 was undetectable in supernatant (Fig10b).  
The production of IL-2 and CD25 in T cells is induced by signalling via the TCR 
(Acuto and Michel, 2003) and supported by co-stimulation via CD80/86 to CD28, 
which lowers the number of TCR that need to be triggered (Viola and Lanzavecchia, 
1996). Presumably, the low IL-2 production by LSEC primed T cells was the result of 
insufficient co-stimulation, as LSEC only express low numbers of CD80/86. 
Furthermore, CD80/86 is not upregulated by LSEC upon antigen specific T cell 
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interaction as is the case for DC (Diehl et al., 2008; Sharpe and Freeman, 2002). Cross-
presentation in DC which was found to be lower at a given antigen concentration than in 
LSEC (Fig 2), could still induce robust IL-2 production by naïve T cells. Most likely 
DC achieve this strong activation by enhancing TCR signalling via co-stimulation. 
It is important to note that naïve T cells albeit the lack of intrinsic IL-2 production, upon 
priming by LSEC, initially upregulated CD25. This finding clearly shows that T cells 
were able to respond to IL-2 but limited in its production. This implies that LSEC do 
not inhibit IL-2 responsiveness in T cells, but do at low antigen concentrations not 
support itsexpression.  
To evaluate if LSEC principally were capable of promoting IL-2 production in T cells, 
the concentration of antigen given to co-cultures was increased to promote stronger 
cross-presentation by LSEC. Increased cross-presentation should result in enhanced 
TCR triggering. Indeed these experiments revealed that the efficient cross-presentation 
mediated by LSEC could at high antigen concentrations (OVA 1mg/ml) trigger the TCR 
sufficiently to induce IL-2 production by T cells. The IL-2 released during priming led 
to an activated state in T cells, which produced levels of IL-2 and IFNγ upon 
restimulation comparable to T cells primed by DC. This indicates that IL-2 can function 
as a mediator of co-stimulation complementing co-stimulation by LSEC. 
Furthermore, strong TCR signalling caused increased expression of CD25 on T cells 
which remained up-regulated, demonstrating a prolonged sensitivity to IL-2. 
Presumably, IL-2 was partially responsible for the upregulation of it’s own receptor 
(Goebel et al., 2006). 
However, even strong priming by LSEC did not induce the shedding of CD62L which 
would allow T cells to home to LN. Again, this observation could be attributed to the 
low amount of CD80/86 expressed by LSEC being insufficient to mediate CD62L 
shedding. The same observation can be made for CD80/86 deficient DC (data not 
shown). Subsequent to an initial downregulation of CD62L during priming, no 
significant difference in CD62L expression in LSEC activated or tolerized T cells could 
be seen at later time points (data not shown), while DC activated T cells remained 
CD62L low. This finding indicates that CD80/86 signalling is essential for CD62L 
shedding while IL-2 is not, as T cell secreted or even exogenously added IL-2 did not 
mediate a significant reduction (Fig. 10c and data not shown). In support of this notion 
is the finding that CD62L downregulation could be induced in rats treated with a CD28 
specific antibody (Muller et al., 2008).  
My findings show that LSEC can mediate a strong TCR signal (signal 1) due to a high 
amount of cross-presented antigen and activate T cells. The strong TCR signal could 
induce IL-2 production augmenting the low CD80/86 expression.  
In this system IL-2 seemed to be the most relevant influence on overcoming tolerance 
induction by LSEC. To ascertain that T cell activation by LSEC was indeed induced 
solely by IL-2, IL-2 was blocked by a functional antibody added to the culture. 
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Blocking IL-2 signalling to T cells during priming rescued tolerance induction by 
LSEC. 
5.11 TCR triggering by LSEC is responsible for IL-2 induction 
As LSEC deliver little co-stimulation, strong TCR signalling must be primarily 
responsible for T cell intrinsic IL-2 production. It has been described that TCR 
signalling alone can trigger IL-2 production and proliferation if the TCR occupancy is 
high enough (Acuto and Michel, 2003). A high TCR occupancy could be facilitated by 
high numbers of TCR expressed on OT-I T cells resulting in high T cell avidity. 
For further validation of the importance of TCR signalling strength for activation of T 
cells by intrinsic IL-2 production, peptide pulsed LSEC or DC were cultured with naïve 
T cells derived from the transgenic St35 line. St35 CD8+ T cells recognize a peptide 
derived from adenovirus E1a protein SGPSNTPPEI on H2Kb. In contrast to OT-I T 
cells they show low avidity due to approximately 5 fold lower TCR expression (Fig 
11a). St35 T cells should therefore not be activated by LSEC if TCR signalling was the 
essential trigger for T cell stimulation by IL-2 production. Indeed this was observed; 
St35 T cells could not be induced to produce detectable amounts of IL-2 during priming 
even at high antigen concentrations presented on LSEC (Fig.11b). This implies that in 
case of low avidity and low co-stimulation, TCR signalling is not sufficient to activate 
intrinsic IL-2 production. Although overall cytokine production was strongly reduced 
compared to OT-I T cells, St35 T cells were not unresponsive per se. DC could activate 
St35 T cells by delivering TCR signals in conjunction with co-stimulation via CD80/86. 
Furthermore St35 T cells showed full activation if exogenous IL-2 was added to LSEC 
culture during priming, supporting the hypothesis that IL-2 mediates the decision 
between tolerance induction and activation of naïve CD8+ T cells by LSEC.  
T cells with high avidity receptors are usually not reactive with self, as they are depleted 
during negative selection in the thymus (Palmer, 2003). It is therefore likely that high 
avidity T cells are specific for foreign antigen. During infection their responsiveness 
might favour activation by cross-presenting LSEC, over tolerance induction. 
Furthermore, IL-2 production by naïve high avidity and possibly memory T cells upon 
antigen encounter could potentially further promote T cell activation within the liver. 
Indeed it has been observed that memory T cells are able to produce sufficient amounts 
of IL-2 to inhibit induction of T cell tolerance by LSEC in vitro (Limmer unpublished 
data). 
5.12 T cells primed by LSEC in the presence of co-stimulation do not 
exhibit cytotoxicity 
Surprisingly, T cells which had been activated by LSEC and showed strong IFNγ and 
IL-2 production upon restimulation, displayed no cytotoxicity. This discrepancy in 
cytokine production and missing cytotoxicity could result from: Firstly, an insufficient 
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amount of IL-2 produced by T cells during priming to cause full activation, as the 
strength of T cell activation was directly correlated to the amount of IL-2 present during 
priming (Fig 9a). Secondly, an insufficient amount of co-stimulation given by LSEC in 
combination with completely missing signal 3 e.g. IL-12 could not induce cytotoxicity.  
Thirdly, missing cytotoxicity could result from actively co-inhibiting T cells via 
programmed death-1 (PD-1) B7-H1 interaction, the latter of which is constitutively 
expressed on LSEC. B7-H1 is a member of the B7 family delivering co-inhibitory 
signals (Collins et al., 2005).  
B7-H1 interaction with PD-1 has been shown to be mandatory and sufficient for 
tolerance induction by LSEC. LSEC deficient in B7-H1 induce T cell immunity (Diehl 
et al., 2008). In another study blocking B7-H1/ PD-1 interaction during chronic hepatitis 
B was shown to lead to the recovery of some virus specific T cell functions (Lopes et 
al., 2008), which could indicate the involvement of LSEC in tolerance induction 
towards hepatic viruses. Importantly, B7-H1 was found to be upregulated on LSEC but 
not on DC in response to interaction with T cells (Diehl et al., 2008). The increase in 
B7-H1 surface expression on LSEC was directly correlated to the strength of interaction 
between LSEC and T cells (Fig. 13b). Therefore the amount of peptide cross-presented 
in combination with the T cell avidity determines the strength of inhibitory signal 
delivered. Thus T cells receiving a strong signal 1 will also receive a strong inhibitory 
signal by LSEC which could counteract full activation. This finding suggests a fine 
balance between TCR, co-stimulatory and co-inhibitory signalling delivered to T cells 
by LSEC. 
5.13 B7-H1 mediated co-inhibition counteracts IL-2 production by T 
cells  
PD-1 on T cells is transiently upregulated during priming which has recently been 
reported to be initiated by NFATc1 (Oestreich et al., 2008). NFATc1 is upregulated in 
response to TCR and co-stimulatory signals and promotes also IL-2 expression 
(Macian, 2005; Serfling et al., 2006).  
Upon interaction with LSEC T cells upregulate PD-1 which can then bind to B7-H1 on 
LSEC promoting tolerance induction in T cells (Diehl et al., 2008).  
The upregulation of PD-1 on T cells, was correlated to the amount of antigen presented 
by LSEC (data not shown). This observation indicates that increased TCR signalling led 
to upregulation of PD-1, presumably via NFAT activation. As B7-H1 was also 
increased in proportion to the amount of cross-presented antigen, strong cross-
presentation can lead to strong co-inhibition. 
To test the hypothesis that co-inhibition through B7-H1 on LSEC is mediated by 
negatively influencing IL-2 production by T cells, IL-2 production during priming by 
B7-H1 deficient LSEC was examined. 
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Priming by B7-H1 deficient LSEC led to significantly increased IL-2 production by T 
cells compared to those primed by wild type LSEC. It is interesting to speculate that 
B7-H1 signalling inhibits IL-2 production, possibly via PD-1 delivering a negative 
feedback signal for NFATc1 activation. 
Furthermore, priming by B7-H1 deficient LSEC resulted in an up to 10 fold increase in 
surface expression of CD25 on T cells, thereby additionally increasing sensitivity to IL-
2 mediated signalling. In line with the observation made in naïve T cells primed by wild 
type LSEC the amount of IL-2 produced upon priming in the absence of B7-H1 was 
directly proportional to the amount of presented antigen and therefore to the strength of 
signal 1. In case of presentation of very low amounts of antigen T cells primed by B7-
H1 deficient LSEC did not produce IL-2 and were not activated. The same was true 
when applying an IL-2 blocking antibody to the culture at high amounts of antigen. T 
cells receiving a strong signal 1 by B7-H1 deficient LSEC in the absence of IL-2 neither 
showed cytokine production upon restimulation, nor any cytotoxicity (Fig 13e). This 
finding indicates that full activation of T cells by LSEC lacking B7-H1 is mediated by 
the increased IL-2 production induced by missing co-inhibition.  
5.14 Conclusion 
My results show that LSEC are the hepatic cell population which is most efficient in the 
uptake of soluble antigen from the circulation. Strong scavenger activity in LSEC is 
accompanied by robust cross-presentation which is even superior to that seen in DC. In 
contrast to DC, LSEC utilise several receptors to take up antigen for cross-presentation. 
Scavenger and mannose receptor shuttle into the same early endosomal compartment, 
potentially increasing the quantity of internalized antigen. The efficiency of antigen 
uptake might compensate for the apparent lack of a compartment dedicated exclusively 
to cross-presentation. 
The early endosomes in LSEC are not stable, but rapidly develop and are most likely 
not the site for antigen loading. The compartment in which peptides for cross-
presentation are loaded in LSEC remains elusive.  
The onset of cross-presentation in LSEC is very fast. However, antigen is not 
sequestered in LSEC, but cleared with a half life of only 6 hours. Antigen clearance is 
accompanied by rapid decline in cross-presentation. In DC, cross-presentation remains 
unaffected during the same time period. Clearly, LSEC and DC employ cross-
presentation mechanisms with very different dynamics and kinetics. 
The short duration of cross-presentation in LSEC suggests that only antigens which are 
present in the circulation for prolonged time are sufficiently presented. Furthermore, 
immune complexed antigens were only weakly presented by LSEC, indicating a 
mechanism for the prevention of tolerance induction towards antigens targeted by an 
immune response. 
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LSEC induce T cell tolerance towards soluble antigens (Limmer et al., 2000). However, 
I could show that LSEC can also induce activation of naïve CD8+ T cells when 
delivering a strong signal 1. The highly efficient cross-presentation mediated by LSEC 
in combination with naïve T cells expressing receptors of high avidity leads to the 
production of T cell intrinsic IL-2 during priming albeit low co-stimulation. IL-2 can 
overcome tolerance induction by LSEC indicating that IL-2 functions as a co-
stimulatory molecule. Furthermore, the presence or absence of IL-2 during priming by 
LSEC ultimately decides whether immunity or tolerance is induced.  
The co-inhibitory molecule B7-H1 is constitutively expressed on LSEC, but upregulated 
in response to T cell interaction (Diehl et al., 2008). This upregulation is directly 
proportional to the strength of MHC-TCR interaction. Thus T cells receiving a strong 
signal 1 will at the same time receive strong inhibitory signals. When LSEC are 
deficient in B7-H1, T cells are activated to become cytotoxic T cells. This activation is 
caused by robust IL-2 production by T cells during priming. When IL-2 is blocked, 
tolerance induction in the absence of B7-H1 commences. These findings clearly suggest 
a role for B7-H1 in counteracting IL-2 production.  
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Abbreviations 
°C degree Celsius 
µ micro 
ABTS 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) 
AcLDL Acetylated low density protein 
AGE Advanced glycation end products 
AICD  activation induced cell death 
AIRE Autoimmune regulator 
APC antigen presenting cell, allophycocyanin 
B7-H1 B7-Homolog 1 
Bcl-2 B cell lymphoma 2 
BSA bovine serum albumin 
CD Cluster of differentiation 
CFSE Carboxy Fluorescein Succinimidyl Ester 
CTL  cytotoxic T lymphocytes 
CTLA-4  cytotoxic T-lymphocyte antigen 4 
DC  dendritic cells 
DesTCR Desiré TCR 
DMEM Dulbecco’s Modified Eagle’s Medium 
DNA Deoxyribonucleic acid 
e.g. lat.: exempli gratia (for example) 
EDTA ethylenediaminetetraacetic acid 
EEA1 Early endosomal antigen 1 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
et al. lat.: Et alteres (and others) 
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FACS Fluorescence activated cell sorting 
FCS Fetal calf serum 
FcγR Receptor recognizing the constant region of immunoglobulin G  
Fig. Figure 
FITC Fluorescein isothiocyanat 
g gravity, gram 
GBSS Gey’s Balanced Salt Solution 
h Hour 
H-2 Histocompatibility-2 
HDC Hepatic dendritic cell 
HSC Hepatic stellate cell 
i.v. Intra venous 
ICAM Intercellular adhesion molecule 
IFN Interferon 
IL  Interleukin 
IMDM Iscove's Modified Dulbecco's  Medium 
iTreg  induced regulatory T cells 
KC Kupffer cell 
l Litre 
LPS Lipopolysaccharide 
LSEC  liver sinusoidal endothelial cells 
LN Lymph node 
m meter, milli 
M Molar 
MACS magnetic cell separation 
MHC  Major Histocompatibility complex 
min minute 
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MR  Mannose receptor 
mTEC  medullary thymic epithelial cells 
MW Molecular weight 
n nano 
NFAT Nuclear factor of activated T cells 
NK natural killer - 
NKT natural killer T - 
nTreg  natural regulatory T cells 
OD optical densitiy 
OVA ovalbumin 
OxLDL Oxidised low density protein 
PAMP  pathogen associated molecular pattern 
PBS phosphate buffered saline 
PD-1  Programmed death 1 
PE phycoerythrin 
PGE2 prostaglandin E2 
pH lat.: potential hydrogenii 
poly I Polyinosinic potassium acid 
PRR  Pattern recognition receptor 
RT room temperature 
SA streptavidin 
SD Standard deviation 
sec second 
SEM Standard error of the mean 
S8L ovalbumin peptide 
SR Scavenger receptor 
TAE Tris-acetate-EDTA  
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Abbreviations 
TAP Transporter associated with antigen processing 
TCR  T cell receptor 
TGF-β  transforming growth factor β 
Th helper T - 
TLR Toll-like receptor 
TMB 3,3’,5,5’-Tetramethylbenzidine 
TNF-α  tumour necrosis factor α 
U Unit 
V Volt 
v/v volume per volume 
VCAM Vascular adhesion molecule 
w/v weight per volume 
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